PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
6169688-1	1981	Specific detection of iota-Carrageenan (i-CAR) at the ultrastructural level has been obtained by coupling with ruthenium red (RR) - an electron microscopic stain.	Carrageenan	22-38	CXADR pseudogene 1	Homo sapiens	42-45
6169688-1	1981	Specific detection of iota-Carrageenan (i-CAR) at the ultrastructural level has been obtained by coupling with ruthenium red (RR) - an electron microscopic stain.	Ruthenium Red	111-124	CXADR pseudogene 1	Homo sapiens	42-45
6169688-1	1981	Specific detection of iota-Carrageenan (i-CAR) at the ultrastructural level has been obtained by coupling with ruthenium red (RR) - an electron microscopic stain.	Ruthenium Red	126-128	CXADR pseudogene 1	Homo sapiens	42-45
6169688-2	1981	The i-CAR-RR complex showed electron density on carbon layers.	Carbon	48-54	CXADR pseudogene 1	Homo sapiens	6-9
34008860-5	2021	The results demonstrated that at a non-toxic dose range (25 to 75 microM), 24-hr treatment of resveratrol was able to suppress the migration and invasion capacities of CAR cells dose dependently.	Resveratrol	94-105	CXADR pseudogene 1	Homo sapiens	168-171
33051739-7	2021	RESULTS: Fifty-four patients underwent DP-CAR between 2008 and 2018.	Dipyridamole	39-41	CXADR pseudogene 1	Homo sapiens	42-45
34032449-1	2021	(S)-carvedilol (S-CAR) is the dominant pharmacodynamic conformation of carvedilol, but its further development for extended-release formulation is restricted by its poor solubility.	Carvedilol	0-14	CXADR pseudogene 1	Homo sapiens	18-21
34032449-1	2021	(S)-carvedilol (S-CAR) is the dominant pharmacodynamic conformation of carvedilol, but its further development for extended-release formulation is restricted by its poor solubility.	Carvedilol	4-14	CXADR pseudogene 1	Homo sapiens	18-21
34003300-0	2022	Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.	Lenalidomide	0-12	CXADR pseudogene 1	Homo sapiens	48-51
34003300-1	2022	We report successful clinical experience using anti-BCMA CAR-T combined with lenalidomide in a patient who was refractory to a previous CAR-T treatment.	Lenalidomide	77-89	CXADR pseudogene 1	Homo sapiens	136-139
33684225-2	2021	We described our institutional experience with arterial reconstruction during DP-CAR.	Dipyridamole	78-80	CXADR pseudogene 1	Homo sapiens	81-84
34010392-0	2021	Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells.	piggybac	83-91	CXADR pseudogene 1	Homo sapiens	15-18
34008860-8	2021	In conclusion, the signaling cascade for resveratrol"s suppression of cisplatin-resistant human oral cancer CAR cells was revealed and summarized.	Resveratrol	41-52	CXADR pseudogene 1	Homo sapiens	108-111
34008860-8	2021	In conclusion, the signaling cascade for resveratrol"s suppression of cisplatin-resistant human oral cancer CAR cells was revealed and summarized.	Cisplatin	70-79	CXADR pseudogene 1	Homo sapiens	108-111
33984717-16	2021	Multivariate analysis showed that higher Tregs at 1 week after infusion was the independently factor for poor RFS (P = 0.032) and shorter OS (P = 0.025) in R/R B-ALL patients with CD19 CAR-T therapy.	tregs	41-46	CXADR pseudogene 1	Homo sapiens	185-188
33984717-18	2021	CONCLUSION: Higher circulating Tregs, especially 1 week after CD19 CAR-T cell infusion, was a poor predict indicator for CD19 CAR-T therapy in R/R B-ALL patients.	tregs	31-36	CXADR pseudogene 1	Homo sapiens	67-70
33984717-18	2021	CONCLUSION: Higher circulating Tregs, especially 1 week after CD19 CAR-T cell infusion, was a poor predict indicator for CD19 CAR-T therapy in R/R B-ALL patients.	tregs	31-36	CXADR pseudogene 1	Homo sapiens	126-129
33921838-2	2021	METHODS: A meta-analysis of studies comparing DP-CAR and standard DP in patients with pancreatic adenocarcinoma was conducted.	Dipyridamole	46-48	CXADR pseudogene 1	Homo sapiens	49-52
33932067-0	2021	Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.	ibrutinib	0-9	CXADR pseudogene 1	Homo sapiens	45-48
33932067-8	2021	The successful outcome of the second-time anti-CD19-CAR T-cell therapy might suggest that the previous ibrutinib treatment improved the activities of anti-CD19-CAR T cells.	ibrutinib	103-112	CXADR pseudogene 1	Homo sapiens	52-55
33932067-8	2021	The successful outcome of the second-time anti-CD19-CAR T-cell therapy might suggest that the previous ibrutinib treatment improved the activities of anti-CD19-CAR T cells.	ibrutinib	103-112	CXADR pseudogene 1	Homo sapiens	160-163
33883175-7	2021	Furthermore, BMMSC-mediated resistance against CAR T cells was effectively modulated by FL118, an inhibitor of anti-apoptotic proteins Survivin, Mcl-1, and XIAP.	7-ethyl-7-hydroxy-10H-1,3-Dioxolo(4,5-g)pyrano(3',4':6,7)indolizino(1,2-b)quinoline-8,11(7H,12H)-dione	88-93	CXADR pseudogene 1	Homo sapiens	47-50
33921838-10	2021	Considering the different baseline tumor characteristics, DP-CAR may need to be compared with palliative therapies instead of standard DP.	Dipyridamole	58-60	CXADR pseudogene 1	Homo sapiens	61-64
32814980-0	2021	Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT.	Fluorodeoxyglucose F18	108-115	CXADR pseudogene 1	Homo sapiens	77-80
33890704-6	2021	Treatment with metamizole, a CAR-dependent inducer of CYP2B6, CYP2C9, CYP2C19 and CYP3A4, accentuated the effect of deglucuronidation on AUC and MR.	Dipyrone	15-25	CXADR pseudogene 1	Homo sapiens	29-32
33948575-2	2021	Kosti et al.1 demonstrate that this form of toxicity can be prevented by designing a CAR whose expression is controlled by oxygen levels in the tumor environment.	Oxygen	123-129	CXADR pseudogene 1	Homo sapiens	85-88
33921838-8	2021	CONCLUSIONS: DP-CAR was not associated with higher mortality compared to standard DP; however, overall morbidity was higher.	Dipyridamole	13-15	CXADR pseudogene 1	Homo sapiens	16-19
33385585-1	2021	Axicabtagene ciloleucel or axi-cel (CD19-CAR T-cells) has been recently approved for refractory/ relapsed diffuse large B cell lymphoma and primary mediastinal B-cell lymphoma.	axicabtagene	0-12	CXADR pseudogene 1	Homo sapiens	41-44
33168933-0	2021	Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?	axicabtagene	0-12	CXADR pseudogene 1	Homo sapiens	24-27
33526385-5	2021	RESULTS: All patients who underwent DP-CAR had tumor contact with the celiac axis.	dp	36-38	CXADR pseudogene 1	Homo sapiens	39-42
33385585-11	2021	In conclusion, we developed a sensitive and accurate qPCR assay for the quantification of transgenic CAR T-cells, which can be a useful additional tool for the monitoring of patients treated with of axi-cel.	axi-cel	199-206	CXADR pseudogene 1	Homo sapiens	101-104
33526385-7	2021	The pretreatment tumor size of patients who underwent DP-CAR was larger (P < 0.001), and rates of blood transfusion (P = 0.003) and postoperative complications (P = 0.016) were higher in patients who underwent DP-CAR compared with patients who underwent DP.	dp	54-56	CXADR pseudogene 1	Homo sapiens	57-60
33526385-10	2021	CONCLUSIONS: DP-CAR following neoadjuvant chemotherapy for patients with borderline resectable or locally advanced pancreatic body carcinoma may bring the same survival impact as DP, despite increased morbidity.	dp	13-15	CXADR pseudogene 1	Homo sapiens	16-19
33636214-2	2021	There are two main bile acid activated receptors, FXR and GPBAR1, that are exclusively activated by bile acids, while other receptors CAR, LXRs, PXR, RORgammaT, S1PR2and VDR are activated by bile acids in addition to other more selective endogenous ligands.	Bile Acids and Salts	191-201	CXADR pseudogene 1	Homo sapiens	134-137
32835415-8	2021	Water holding capacity increased significantly by 32.33% in the presence of 0.10% kappa-CAR addition.	Water	0-5	CXADR pseudogene 1	Homo sapiens	88-91
33833576-9	2021	Patients with resectable CRC with dMMR were more likely to have higher levels of neutrophil, monocyte, platelet, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), C-reactive protein to albumin ratio (CAR), Glasgow prognostic score (GPS) and C-reactive protein (CRP).	dmmr	34-38	CXADR pseudogene 1	Homo sapiens	254-257
33833576-10	2021	In patients with dMMR, those with higher levels of PLR, MLR, CAR, and co-effect present had shorter overall survival (OS) significantly.	dmmr	17-21	CXADR pseudogene 1	Homo sapiens	61-64
33902267-9	2022	Conclusions: CAR and CLR measured on day 3 post infliximab salvage for steroid-refractory ASUC represent simple and routinely performed biomarkers that appear to be strong predictors of colectomy.	Steroids	71-78	CXADR pseudogene 1	Homo sapiens	13-16
33355212-10	2021	Whereas omeprazole induced CYP3A4 (up to 5.3-fold, geomean, n = 4 experiments), CAR activators phenytoin and CITCO did not.	Phenytoin	95-104	CXADR pseudogene 1	Homo sapiens	80-83
33717142-0	2021	GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells.	guanosine 5'-monophosphorothioate	0-3	CXADR pseudogene 1	Homo sapiens	131-134
33635343-1	2021	CD133 + cancer stem cells mediate chemoresistance in multiple aggressive cancers, and anti-CD133 chimeric antigen receptor T (CAR-T) cells are designed to selectively target cisplatin-resistant gastric cancer stem cells in this investigation.	Cisplatin	174-183	CXADR pseudogene 1	Homo sapiens	126-129
33635343-7	2021	Anti-CD133 CAR-T cells exhibited pronounced killing efficiency against cisplatin-exposed CD133+ BGC-823 cells with up-regulated activation markers and cytotoxicity cytokine production.	Cisplatin	71-80	CXADR pseudogene 1	Homo sapiens	11-14
33717142-7	2021	This novel approach allowed the expansion of highly pure GMP-grade CAR NK cells at optimal cell numbers to be used for adoptive CAR NK cell-based cancer immunotherapy.	guanosine 5'-monophosphorothioate	57-60	CXADR pseudogene 1	Homo sapiens	67-70
33717142-7	2021	This novel approach allowed the expansion of highly pure GMP-grade CAR NK cells at optimal cell numbers to be used for adoptive CAR NK cell-based cancer immunotherapy.	guanosine 5'-monophosphorothioate	57-60	CXADR pseudogene 1	Homo sapiens	128-131
33563660-3	2021	Expression of GM18 in CAR T-cells enhanced their effector function in an antigen- and activation-dependent manner.	gm18	14-18	CXADR pseudogene 1	Homo sapiens	22-25
33417830-4	2021	in this issue demonstrate that oxaliplatin-based lymphodepleting chemotherapy promotes enhanced CAR T cell recruitment to lung tumors, boosting therapeutic impact in combination with anti-PD-L1.	Oxaliplatin	31-42	CXADR pseudogene 1	Homo sapiens	96-99
33563660-5	2021	In vivo, CAR.GM18 T-cells induced tumor regression at cell doses at which standard CAR T-cells were ineffective in two solid tumor xenograft models.	gm18	13-17	CXADR pseudogene 1	Homo sapiens	9-12
33563660-5	2021	In vivo, CAR.GM18 T-cells induced tumor regression at cell doses at which standard CAR T-cells were ineffective in two solid tumor xenograft models.	gm18	13-17	CXADR pseudogene 1	Homo sapiens	83-86
33303326-11	2021	To determine whether the GXMR-CAR+ T cells exhibited GXM-specific recognition, these cells were incubated with GXM for 24 h and examined with the use of brightfield microscopy.	glucuronoxylomannan	25-28	CXADR pseudogene 1	Homo sapiens	30-33
33557164-6	2021	This deviation was attributed to hydrogen bonds of CAR with TRP ether groups.	Hydrogen	33-41	CXADR pseudogene 1	Homo sapiens	51-54
33557164-6	2021	This deviation was attributed to hydrogen bonds of CAR with TRP ether groups.	Tryptophan	60-63	CXADR pseudogene 1	Homo sapiens	51-54
33442977-1	2021	Reaction of aryl 2-pyridyl ethers with arylzinc reagents under catalysis of NiCl2(PCy3)2 affords aryl-aryl cross-coupling products via selective cleavage of CAr-OPy bonds.	aryl 2-pyridyl ethers	12-33	CXADR pseudogene 1	Homo sapiens	157-160
33442977-1	2021	Reaction of aryl 2-pyridyl ethers with arylzinc reagents under catalysis of NiCl2(PCy3)2 affords aryl-aryl cross-coupling products via selective cleavage of CAr-OPy bonds.	arylzinc reagents	39-56	CXADR pseudogene 1	Homo sapiens	157-160
33442977-1	2021	Reaction of aryl 2-pyridyl ethers with arylzinc reagents under catalysis of NiCl2(PCy3)2 affords aryl-aryl cross-coupling products via selective cleavage of CAr-OPy bonds.	BIS(TRICYCLOHEXYLPHOSPHINE)NICKEL(II) CHLORIDE	76-88	CXADR pseudogene 1	Homo sapiens	157-160
33382402-3	2021	CAR T cells generated from Th/Tc17 cells given with the STING agonists DMXAA or cGAMP greatly enhanced tumor control, which was associated with enhanced CAR T cell persistence in the TME.	vadimezan	71-76	CXADR pseudogene 1	Homo sapiens	0-3
33352191-9	2021	Moreover, our results preliminarily indicate that compared with the other two treatments, Soluble-SA-CK and Standard-CK, adding cytokine-coupled biotin magnetic beads more effectively increases the proliferation rate of CD19 CAR T cells.	Biotin	145-151	CXADR pseudogene 1	Homo sapiens	225-228
33382529-0	2021	Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China.	relmacabtagene	0-14	CXADR pseudogene 1	Homo sapiens	43-46
33382402-3	2021	CAR T cells generated from Th/Tc17 cells given with the STING agonists DMXAA or cGAMP greatly enhanced tumor control, which was associated with enhanced CAR T cell persistence in the TME.	vadimezan	71-76	CXADR pseudogene 1	Homo sapiens	153-156
33382402-3	2021	CAR T cells generated from Th/Tc17 cells given with the STING agonists DMXAA or cGAMP greatly enhanced tumor control, which was associated with enhanced CAR T cell persistence in the TME.	cyclic guanosine monophosphate-adenosine monophosphate	80-85	CXADR pseudogene 1	Homo sapiens	0-3
33382402-3	2021	CAR T cells generated from Th/Tc17 cells given with the STING agonists DMXAA or cGAMP greatly enhanced tumor control, which was associated with enhanced CAR T cell persistence in the TME.	cyclic guanosine monophosphate-adenosine monophosphate	80-85	CXADR pseudogene 1	Homo sapiens	153-156
33382402-4	2021	Using single-cell RNA sequencing, we demonstrate that DMXAA promoted CAR T cell trafficking and persistence, supported by the generation of a chemokine milieu that promoted CAR T cell recruitment and modulation of the immunosuppressive TME through alterations in the balance of immune-stimulatory and suppressive myeloid cells.	vadimezan	54-59	CXADR pseudogene 1	Homo sapiens	69-72
33382402-4	2021	Using single-cell RNA sequencing, we demonstrate that DMXAA promoted CAR T cell trafficking and persistence, supported by the generation of a chemokine milieu that promoted CAR T cell recruitment and modulation of the immunosuppressive TME through alterations in the balance of immune-stimulatory and suppressive myeloid cells.	vadimezan	54-59	CXADR pseudogene 1	Homo sapiens	173-176
33314568-0	2021	Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy.	ruxolitinib	0-11	CXADR pseudogene 1	Homo sapiens	52-55
32967009-9	2021	We observed durable CAR T-cell persistence after CART2 in patients who received Cy-Flu lymphodepletion before CART1 and a higher CART2 compared to CART1 cell dose.	cy-flu	80-86	CXADR pseudogene 1	Homo sapiens	20-23
33462245-0	2021	Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming.	Decitabine	9-19	CXADR pseudogene 1	Homo sapiens	35-38
33462245-8	2021	In vitro administration of decitabine may represent an option for the generation of CAR T cells with improved anti-tumour properties.	Decitabine	27-37	CXADR pseudogene 1	Homo sapiens	84-87
33314568-11	2021	In vitro assays revealed that ruxolitinib could dampen CAR T expansion and cytotoxicity, suggesting that the timing and dosage of ruxolitinib should be carefully considered to avoid dampening anti-leukaemia response.	ruxolitinib	30-41	CXADR pseudogene 1	Homo sapiens	55-58
33249873-2	2021	Patients undergoing CAR-T cell therapy are at increased risk of infection due to prior immunosuppression, lymphodepleting chemotherapy, treatment of unique toxicities with tocilizumab and/or steroids, on-target effects of hypogammaglobulinaemia, and prolonged cytopenias.	Steroids	191-199	CXADR pseudogene 1	Homo sapiens	20-23
32624316-6	2021	RESULTS: AITC decreased CAR cell viability, induced cell death of CAR cells and inhibited the confluences of cultured CAR cells.	allyl isothiocyanate	9-13	CXADR pseudogene 1	Homo sapiens	24-27
32624316-6	2021	RESULTS: AITC decreased CAR cell viability, induced cell death of CAR cells and inhibited the confluences of cultured CAR cells.	allyl isothiocyanate	9-13	CXADR pseudogene 1	Homo sapiens	66-69
32624316-6	2021	RESULTS: AITC decreased CAR cell viability, induced cell death of CAR cells and inhibited the confluences of cultured CAR cells.	allyl isothiocyanate	9-13	CXADR pseudogene 1	Homo sapiens	66-69
32624316-7	2021	When CAR cells were treated with AITC, activation of caspase-3 and caspase-9 by AITC was observed and could be reversed by Z-VAD-fmk (pan-caspase inhibitor).	allyl isothiocyanate	33-37	CXADR pseudogene 1	Homo sapiens	5-8
32624316-7	2021	When CAR cells were treated with AITC, activation of caspase-3 and caspase-9 by AITC was observed and could be reversed by Z-VAD-fmk (pan-caspase inhibitor).	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	123-132	CXADR pseudogene 1	Homo sapiens	5-8
32624316-8	2021	Furthermore, the protein expressions of phosphorylated protein kinase B (p-AKT) and phosphorylated mammalian target of rapamycin (p-mTOR) were suppressed in AITC-treated CAR cells, whereas protein expressions of Bax, cytochrome c, Apaf-1, cleaved caspase-3, and cleaved caspase-9 were upregulated in AITC-treated CAR cells.	allyl isothiocyanate	157-161	CXADR pseudogene 1	Homo sapiens	170-173
32624316-8	2021	Furthermore, the protein expressions of phosphorylated protein kinase B (p-AKT) and phosphorylated mammalian target of rapamycin (p-mTOR) were suppressed in AITC-treated CAR cells, whereas protein expressions of Bax, cytochrome c, Apaf-1, cleaved caspase-3, and cleaved caspase-9 were upregulated in AITC-treated CAR cells.	allyl isothiocyanate	157-161	CXADR pseudogene 1	Homo sapiens	313-316
32624316-9	2021	CONCLUSION: AITC can inhibit Akt/mTOR proliferation signaling and promote mitochondria-dependent apoptotic pathway through AITC-enhanced activities of caspase-3 and caspase-9 in CAR cells.	allyl isothiocyanate	12-16	CXADR pseudogene 1	Homo sapiens	178-181
32624316-9	2021	CONCLUSION: AITC can inhibit Akt/mTOR proliferation signaling and promote mitochondria-dependent apoptotic pathway through AITC-enhanced activities of caspase-3 and caspase-9 in CAR cells.	allyl isothiocyanate	123-127	CXADR pseudogene 1	Homo sapiens	178-181
33339358-1	2020	The emergence and development of car-sharing has not only satisfied people"s diverse travel needs, but also brought new solutions for improving urban traffic conditions and achieving low-carbon and green sustainable development.	Carbon	187-193	CXADR pseudogene 1	Homo sapiens	33-36
33718796-0	2021	Timed Controlled Repeated Rotation of the CAR-170-C NXSTAGE Chronic Cartridge Hemodialysis Filter: A Novel Approach to Enabling Heparin-Free Frequent Daily Home Hemodialysis.	Heparin	128-135	CXADR pseudogene 1	Homo sapiens	42-45
33363008-13	2020	Our results point to a preferred interval of more than 3 months until patients should undergo cell separation for CAR-T therapy in the specific situation post-HD melphalan/autoSCT.	Melphalan	162-171	CXADR pseudogene 1	Homo sapiens	114-117
33077425-11	2020	In steatotic conditions, overexpression of G9a prevented fatty acid mediated decreased expression of CAR, CYP2C19, 2C8, 7A1 and 3A4.	Fatty Acids	57-67	CXADR pseudogene 1	Homo sapiens	101-104
33021872-7	2020	The CAR used was FMC63-28Z; axicabtagene ciloleucel uses the same CAR.	axicabtagene	28-40	CXADR pseudogene 1	Homo sapiens	66-69
33021872-7	2020	The CAR used was FMC63-28Z; axicabtagene ciloleucel uses the same CAR.	ciloleucel	41-51	CXADR pseudogene 1	Homo sapiens	66-69
32998963-0	2020	Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy.	INCB039110	0-10	CXADR pseudogene 1	Homo sapiens	114-117
32998963-0	2020	Itacitinib (INCB039110), a JAK1 inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-Cell Therapy.	INCB039110	12-22	CXADR pseudogene 1	Homo sapiens	114-117
32998963-9	2020	Finally, in an in vivo model, antitumor activity of CD19-CAR T-cells adoptively transferred into CD19+ tumor bearing immuno-deficient animals was unabated by oral itacitinib treatment.	INCB039110	163-173	CXADR pseudogene 1	Homo sapiens	57-60
32998963-10	2020	CONCLUSIONS: Together, these data suggest that itacitinib has potential as a prophylactic agent for the prevention of CAR T-cell-induced CRS, and a phase II clinical trial of itacitinib for prevention of CRS induced by CAR T-cell therapy has been initiated (NCT04071366).	INCB039110	47-57	CXADR pseudogene 1	Homo sapiens	118-121
32998963-10	2020	CONCLUSIONS: Together, these data suggest that itacitinib has potential as a prophylactic agent for the prevention of CAR T-cell-induced CRS, and a phase II clinical trial of itacitinib for prevention of CRS induced by CAR T-cell therapy has been initiated (NCT04071366).	INCB039110	175-185	CXADR pseudogene 1	Homo sapiens	219-222
32925186-6	2020	Most recently, in July 2020 the FDA granted regulatory approval to a third CAR T cell product, Brexucabtagene Autoleucel for mantle cell lymphoma.	brexucabtagene	95-109	CXADR pseudogene 1	Homo sapiens	75-78
33107732-0	2020	Carbon Bond Breaking under Ar+-Ion Irradiation in Dependence on sp Hybridization: Car-Parrinello, Ehrenfest, and Classical Dynamics Study.	Argon	27-29	CXADR pseudogene 1	Homo sapiens	0-3
33107732-0	2020	Carbon Bond Breaking under Ar+-Ion Irradiation in Dependence on sp Hybridization: Car-Parrinello, Ehrenfest, and Classical Dynamics Study.	TFF2 protein, human	64-66	CXADR pseudogene 1	Homo sapiens	0-3
32791399-7	2020	It was worth noting that the target compounds 17a and 25a with excellent antifungal activity (0.125-4 mug/mL) can inhibit the fluconazole-resistant Candida Strain 17#, CaR, 632, and 901 in the range of MIC values (4-8 mug/mL).	Fluconazole	126-137	CXADR pseudogene 1	Homo sapiens	168-171
33120740-9	2020	OUTCOMES: After fludarabine and cyclophosphamide (FC) lymphodepletion chemotherapy, pre-existing CAR-T cells were revitalized and the patient developed grade 2 cytokine release syndrome (CRS) contributing to the regression of relapsed B-cell lymphoma.	fludarabine	16-27	CXADR pseudogene 1	Homo sapiens	97-100
33292642-3	2020	To minimize side effects, we designed a hypoxia-inducible CAR (HiCAR), which is driven by a hypoxia response element (HRE), and consists of a conventional CAR and an oxygen-dependent degradation domain (ODD) that is actively degraded under normoxia but stabilized under hypoxia.	Oxygen	166-172	CXADR pseudogene 1	Homo sapiens	58-61
33292642-3	2020	To minimize side effects, we designed a hypoxia-inducible CAR (HiCAR), which is driven by a hypoxia response element (HRE), and consists of a conventional CAR and an oxygen-dependent degradation domain (ODD) that is actively degraded under normoxia but stabilized under hypoxia.	Oxygen	166-172	CXADR pseudogene 1	Homo sapiens	65-68
32505840-12	2020	The synergetic effect was played by Xiaoaiping injection inhibiting paclitaxel-induced PXR and CAR expression, which subsequently inhibited CYP450 enzymes CYP2C8 and CYP3A4, transporter P-gp and anti-apoptotic proteins Bcl-2 and Bcl-xl in SK-OV-3 cells.	Paclitaxel	68-78	CXADR pseudogene 1	Homo sapiens	95-98
33120740-9	2020	OUTCOMES: After fludarabine and cyclophosphamide (FC) lymphodepletion chemotherapy, pre-existing CAR-T cells were revitalized and the patient developed grade 2 cytokine release syndrome (CRS) contributing to the regression of relapsed B-cell lymphoma.	Cyclophosphamide	32-48	CXADR pseudogene 1	Homo sapiens	97-100
33120740-9	2020	OUTCOMES: After fludarabine and cyclophosphamide (FC) lymphodepletion chemotherapy, pre-existing CAR-T cells were revitalized and the patient developed grade 2 cytokine release syndrome (CRS) contributing to the regression of relapsed B-cell lymphoma.	Fc(alpha) receptor	50-52	CXADR pseudogene 1	Homo sapiens	97-100
33023176-7	2020	Furthermore, it has been observed that increases in salivary cortisol in CAR are associated with small but significant increases in blood lactate levels.	Hydrocortisone	61-69	CXADR pseudogene 1	Homo sapiens	73-76
33102938-4	2021	Briefly, paired chemical groups (N3/BCN) are separately incorporated into CAR-T cell and tumor via nondestructive intrinsic glycometabolism of exogenous Ac4GalNAz and Ac4ManNBCN, serving as an artificial ligand-receptor.	Ac(4)GalNAz	153-162	CXADR pseudogene 1	Homo sapiens	74-77
33102938-4	2021	Briefly, paired chemical groups (N3/BCN) are separately incorporated into CAR-T cell and tumor via nondestructive intrinsic glycometabolism of exogenous Ac4GalNAz and Ac4ManNBCN, serving as an artificial ligand-receptor.	ac4mannbcn	167-177	CXADR pseudogene 1	Homo sapiens	74-77
33021979-8	2020	co-, ortho-planar PCB metabolite exposure results in activation of Car/PxR, Pparalpha (Srebf1,-Lxrbeta), Arnt (AhR-Erbeta), AR, Dio1 (Dio2) and Trbeta limbs with a Delta Cmicro contraction of 0.73 and Delta Cmicro expansion of 1.18 (as compared to p-dioxin).	Polychlorinated Biphenyls	18-21	CXADR pseudogene 1	Homo sapiens	67-70
32798592-3	2020	In this study, hydroxypropyl methylcellulose (HPMC) was co-formulated at 10% (w/w) with carvedilol-L-aspartic acid (CAR-ASP) co-amorphous systems at CAR to ASP molar ratios of 1:1, 1:1.5 and 1:2.	carvedilol-l-aspartic acid	88-114	CXADR pseudogene 1	Homo sapiens	116-119
32798592-3	2020	In this study, hydroxypropyl methylcellulose (HPMC) was co-formulated at 10% (w/w) with carvedilol-L-aspartic acid (CAR-ASP) co-amorphous systems at CAR to ASP molar ratios of 1:1, 1:1.5 and 1:2.	carvedilol-l-aspartic acid	88-114	CXADR pseudogene 1	Homo sapiens	149-152
32798592-3	2020	In this study, hydroxypropyl methylcellulose (HPMC) was co-formulated at 10% (w/w) with carvedilol-L-aspartic acid (CAR-ASP) co-amorphous systems at CAR to ASP molar ratios of 1:1, 1:1.5 and 1:2.	Aspartic Acid	120-123	CXADR pseudogene 1	Homo sapiens	116-119
32798592-5	2020	HPMC was involved in the molecular interactions of the CAR-ASP-HPMC systems, but did not disturb ionic interactions between CAR and ASP.	Aspartic Acid	59-63	CXADR pseudogene 1	Homo sapiens	55-58
32798592-5	2020	HPMC was involved in the molecular interactions of the CAR-ASP-HPMC systems, but did not disturb ionic interactions between CAR and ASP.	Hypromellose Derivatives	0-4	CXADR pseudogene 1	Homo sapiens	55-58
32798592-5	2020	HPMC was involved in the molecular interactions of the CAR-ASP-HPMC systems, but did not disturb ionic interactions between CAR and ASP.	Aspartic Acid	59-62	CXADR pseudogene 1	Homo sapiens	55-58
32798592-6	2020	Addition of HPMC optimized the dissolution of the CAR-ASP systems by reducing the initial dissolution rate and maintaining super-saturation for a longer period.	Hypromellose Derivatives	12-16	CXADR pseudogene 1	Homo sapiens	50-53
32682905-7	2020	For effective PDAC treatment, allogeneic CAR-NK cells were reprogrammed to carry an apoptosis-inducing ligand and to redirect them towards FRalpha and initiate DR4/5-mediated cancer-selective cell death in FRalpha- and DR4/5-positive tumors.	pdac	14-18	CXADR pseudogene 1	Homo sapiens	41-44
32645298-6	2020	Here, we employed the human sodium iodide symporter to non-invasively quantify tumor retention of pan-ErbB family targeted CAR-T by PET.	Sodium Iodide	28-41	CXADR pseudogene 1	Homo sapiens	123-126
33023176-7	2020	Furthermore, it has been observed that increases in salivary cortisol in CAR are associated with small but significant increases in blood lactate levels.	Lactic Acid	138-145	CXADR pseudogene 1	Homo sapiens	73-76
33457105-2	2020	The well-established NK-92 cell line provides a promising alternative to produce CAR-modified effector cells in a GMP-compliant, cost-effective way.	guanosine 5'-monophosphorothioate	114-117	CXADR pseudogene 1	Homo sapiens	81-84
33145312-8	2020	This study set out to analyze the problems in the clinical application of CAR-T therapy encountered in recent years and to introduce corresponding strategies, with the aim of providing a basis of reference for clinicians and scientists in the management of CAR-T therapy in clinical practice and in the CAR-T therapy research.	car-t	74-79	CXADR pseudogene 1	Homo sapiens	257-260
32941648-0	2020	The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome.	alpha-hydroxyglutarate	20-38	CXADR pseudogene 1	Homo sapiens	93-96
32573723-0	2020	Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity.	Arginine	34-42	CXADR pseudogene 1	Homo sapiens	69-72
32573723-2	2020	However, the resulting low arginine microenvironment also impairs chimeric antigen receptor T cells (CAR-T) cell proliferation, limiting their efficacy in clinical trials against haematological and solid malignancies.	Arginine	27-35	CXADR pseudogene 1	Homo sapiens	101-104
32959537-8	2020	CAR above 0 02 was associated with higher carbohydrate antigen 19-9 levels (20 5 versus 66 1 units/ml for CAR of 0 02 or less; P = 0 002), larger tumour size (3 2 versus 4 4 cm respectively; P = 0 031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0 041).	Carbohydrates	42-54	CXADR pseudogene 1	Homo sapiens	0-3
32413717-0	2020	Conformational diversity of the THF molecule in N2 matrix by means of FTIR matrix isolation experiment and Car-Parrinello molecular dynamics simulations.	tetrahydrofuran	32-35	CXADR pseudogene 1	Homo sapiens	107-110
31325134-3	2020	The purpose of this study was to clarify the impact of NAC on surgical outcomes and prognosis in DP-CAR patients.	nac	55-58	CXADR pseudogene 1	Homo sapiens	100-103
32447123-4	2020	And these G-type compounds can further undergo O-CH3, Car-OCH3 and Car-OH bonds cleavage to form biphenolic hydroxyl compounds, phenols and aromatic hydrocarbons.	biphenolic hydroxyl	97-116	CXADR pseudogene 1	Homo sapiens	54-57
32447123-4	2020	And these G-type compounds can further undergo O-CH3, Car-OCH3 and Car-OH bonds cleavage to form biphenolic hydroxyl compounds, phenols and aromatic hydrocarbons.	Phenols	128-135	CXADR pseudogene 1	Homo sapiens	54-57
32447123-4	2020	And these G-type compounds can further undergo O-CH3, Car-OCH3 and Car-OH bonds cleavage to form biphenolic hydroxyl compounds, phenols and aromatic hydrocarbons.	Hydrocarbons, Aromatic	140-161	CXADR pseudogene 1	Homo sapiens	54-57
32817364-2	2020	CAR therapy was initially developed with conventional T cells, which have different signaling requirements than do Tregs To date, most of the CAR Treg studies used second-generation CARs, encoding a CD28 or 4-1BB co-receptor signaling domain and CD3zeta, but it was not known if this CAR design was optimal for Tregs Using a human leukocyte antigen-A2-specific CAR platform and human Tregs, we compared 10 CARs with different co-receptor signaling domains and systematically tested their function and CAR-stimulated gene expression profile.	tregs	311-316	CXADR pseudogene 1	Homo sapiens	0-3
32817364-5	2020	This comprehensive study of CAR signaling domain variants in Tregs can be leveraged to optimize CAR design for use in antigen-specific Treg therapy.	tregs	61-66	CXADR pseudogene 1	Homo sapiens	28-31
32817364-5	2020	This comprehensive study of CAR signaling domain variants in Tregs can be leveraged to optimize CAR design for use in antigen-specific Treg therapy.	tregs	61-66	CXADR pseudogene 1	Homo sapiens	96-99
32817364-5	2020	This comprehensive study of CAR signaling domain variants in Tregs can be leveraged to optimize CAR design for use in antigen-specific Treg therapy.	treg	61-65	CXADR pseudogene 1	Homo sapiens	28-31
32817364-5	2020	This comprehensive study of CAR signaling domain variants in Tregs can be leveraged to optimize CAR design for use in antigen-specific Treg therapy.	treg	61-65	CXADR pseudogene 1	Homo sapiens	96-99
32683485-5	2020	RESULTS: A total of 21 patients went through DP-CAR of whom 15 were preoperatively embolized.	dp	45-47	CXADR pseudogene 1	Homo sapiens	48-51
32683485-9	2020	Median survival in patients who underwent DP and DP-CAR procedures was 24.0 and 23.5 months, respectively (P > 0.5).	dp	49-51	CXADR pseudogene 1	Homo sapiens	52-55
32329959-5	2020	In proof-of-concept studies, this cp-Fab/CAR-T system targeting folate binding sites in the cell surfaceome mediated potent and specific eradication of folate receptor-expressing cancer cells in vitro and in vivo .	Folic Acid	64-70	CXADR pseudogene 1	Homo sapiens	41-44
32758419-4	2020	Blocking CAR ubiquitination by mutating all lysines in the CAR cytoplasmic domain (CARKR) markedly repressed CAR downmodulation by inhibiting lysosomal degradation while enhancing recycling of internalized CARs back to the cell surface.	Lysine	44-51	CXADR pseudogene 1	Homo sapiens	9-12
32758419-4	2020	Blocking CAR ubiquitination by mutating all lysines in the CAR cytoplasmic domain (CARKR) markedly repressed CAR downmodulation by inhibiting lysosomal degradation while enhancing recycling of internalized CARs back to the cell surface.	Lysine	44-51	CXADR pseudogene 1	Homo sapiens	59-62
32758419-4	2020	Blocking CAR ubiquitination by mutating all lysines in the CAR cytoplasmic domain (CARKR) markedly repressed CAR downmodulation by inhibiting lysosomal degradation while enhancing recycling of internalized CARs back to the cell surface.	Lysine	44-51	CXADR pseudogene 1	Homo sapiens	59-62
31325134-11	2020	CONCLUSION: DP-CAR following NAC was associated with a preferable prognosis and had no negative effect on surgical outcomes.	nac	29-32	CXADR pseudogene 1	Homo sapiens	15-18
31325134-12	2020	Therefore, NAC in DP-CAR patients might be a beneficial and safe therapeutic strategy.	nac	11-14	CXADR pseudogene 1	Homo sapiens	21-24
32610498-1	2020	The emergence and development of car sharing can not only satisfy people"s diverse travel demands, but also can bring a new solution to facilitate urban low-carbon and green development.	Carbon	157-163	CXADR pseudogene 1	Homo sapiens	33-36
32060001-3	2020	METHODS: We collected peripheral blood mononuclear cells from healthy donors and patients with HCC and used them to create CAR T cells, based on the hYP7 and HN3 antibodies, which have high affinities for the C-lobe and N-lobe of GPC3, respectively.	Nitrogen	159-160	CXADR pseudogene 1	Homo sapiens	123-126
32521634-5	2020	In this narrative review, we aim to identify literature that has explored the influence of single nucleotide polymorphisms (SNPs) of genes encoding drug transporters and their transcriptional regulators (SLCO1B1, ABCB1, PXR and CAR), metabolizing enzymes (CES1, CES2 and AADAC) and VDR and its pathway regulators (VDR, CYP27B1 and CYP24A1) on plasma RF concentrations in TB patients on antitubercular therapy.	Rifampin	350-352	CXADR pseudogene 1	Homo sapiens	228-231
32119557-4	2020	Salt formation between CAR with ASP or GLU was expected to occur at the molar 1:1 ratio based on their chemical structures.	Salts	0-4	CXADR pseudogene 1	Homo sapiens	23-26
32076701-0	2020	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure.	ibrutinib	94-103	CXADR pseudogene 1	Homo sapiens	42-45
32076701-1	2020	We previously reported durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered (CD19 CAR) T-cell immunotherapy after ibrutinib failure.	ibrutinib	219-228	CXADR pseudogene 1	Homo sapiens	187-190
32076701-2	2020	Because preclinical studies showed that ibrutinib could improve CAR T cell-antitumor efficacy and reduce cytokine release syndrome (CRS), we conducted a pilot study to evaluate the safety and feasibility of administering ibrutinib concurrently with CD19 CAR T-cell immunotherapy.	ibrutinib	40-49	CXADR pseudogene 1	Homo sapiens	64-67
32076701-11	2020	CD19 CAR T cells with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and led to high rates of MRD-negative response by IGH sequencing.	ibrutinib	33-42	CXADR pseudogene 1	Homo sapiens	5-8
32383916-1	2020	A thin-film periodically poled lithium niobate waveguide was designed and fabricated which generates entangled photon pairs at telecommunications wavelengths with high coincidences-to-accidentals counts ratio CAR>67000, two-photon interference visibility V>99%, and heralded single-photon autocorrelation g_{H}^{(2)}(0)<0.025.	lithium niobate	31-46	CXADR pseudogene 1	Homo sapiens	209-212
32320454-4	2020	Signs and symptoms of CRS are usually resolved after steroid administration, but steroids abrogate the expansion and persistence of CAR T cell populations.	Steroids	81-89	CXADR pseudogene 1	Homo sapiens	132-135
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	Carbohydrates	78-90	CXADR pseudogene 1	Homo sapiens	224-227
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	Carbohydrates	78-90	CXADR pseudogene 1	Homo sapiens	336-339
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	Carbohydrates	78-90	CXADR pseudogene 1	Homo sapiens	336-339
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	oligomannose	185-197	CXADR pseudogene 1	Homo sapiens	224-227
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	oligomannose	185-197	CXADR pseudogene 1	Homo sapiens	336-339
32523897-3	2020	We have previously shown that adding a second Env-binding moiety, such as the carbohydrate recognition domain of human mannose-binding lectin (MBL) that recognizes the highly conserved oligomannose patch on gp120, increases CAR potency in an in vitro HIV suppression assay; moreover it reduces the undesired capacity for the CD4 of the CAR molecule to act as an entry receptor, thereby rendering CAR-expressing CD8+ T cells susceptible to infection.	oligomannose	185-197	CXADR pseudogene 1	Homo sapiens	336-339
32462079-3	2020	We adopted a non-viral CAR approach via mRNA electroporation to modify Vgamma9Vdelta2 T cells and demonstrated that, upon interaction with the NKG2D ligand-positive cancer cells, the CARs substantially enhanced the cytotoxic activity of the modified cells toward multiple cultured solid tumor cell lines, including those resistant to Zometa treatment.	Zoledronic Acid	334-340	CXADR pseudogene 1	Homo sapiens	23-26
32267219-8	2020	The major fatty acids of strain CAR-16T were iso-C15 : 0, iso-C15 : 0 3-OH, C16 : 1omega5c and summed feature 3 (C16 : 1omega7c/C16 : 1omega6c and/or iso-C15 : 0 2-OH).	Fatty Acids	10-21	CXADR pseudogene 1	Homo sapiens	32-35
32267219-14	2020	The type strain is CAR-16T (=BCRC 81153T=LMG 30923T=KCTC 62869T).	kctc	52-56	CXADR pseudogene 1	Homo sapiens	19-22
32119557-4	2020	Salt formation between CAR with ASP or GLU was expected to occur at the molar 1:1 ratio based on their chemical structures.	Aspartic Acid	32-35	CXADR pseudogene 1	Homo sapiens	23-26
32119557-4	2020	Salt formation between CAR with ASP or GLU was expected to occur at the molar 1:1 ratio based on their chemical structures.	Glutamic Acid	39-42	CXADR pseudogene 1	Homo sapiens	23-26
32119557-5	2020	Interestingly, the largest deviation between the experimental Tg and the theoretical Tg based on the Gordon-Taylor equation was observed at a molar ratio of around 1:1.5 in CAR-ASP and CAR-GLU systems.	Aspartic Acid	177-180	CXADR pseudogene 1	Homo sapiens	173-176
31776084-0	2020	Toxicity of glyphosate in feed for weanling piglets and the mechanism of glyphosate detoxification by the liver nuclear receptor CAR/PXR pathway.	glyphosate	73-83	CXADR pseudogene 1	Homo sapiens	129-132
32119557-5	2020	Interestingly, the largest deviation between the experimental Tg and the theoretical Tg based on the Gordon-Taylor equation was observed at a molar ratio of around 1:1.5 in CAR-ASP and CAR-GLU systems.	Glutamic Acid	189-192	CXADR pseudogene 1	Homo sapiens	185-188
32119557-7	2020	The highest Tg was found to be at CAR-ASP 1:1.46 and CAR-GLU 1:1.43 mathematically.	Thioguanine	12-14	CXADR pseudogene 1	Homo sapiens	34-43
32119557-7	2020	The highest Tg was found to be at CAR-ASP 1:1.46 and CAR-GLU 1:1.43 mathematically.	Thioguanine	12-14	CXADR pseudogene 1	Homo sapiens	53-62
32068207-7	2020	Resveratrol activated NXRs (CAR/PXR/AHR/Nrf2) signaling pathways and exerted antidotal roles by enhancing the phase I and II detoxification systems to relieve oxidative damage.	Resveratrol	0-11	CXADR pseudogene 1	Homo sapiens	28-31
31291465-5	2020	Multiple receptors such as FXR, GPBAR1, PXR, CAR and VDR act as sensors of bile acids have been reported.	Bile Acids and Salts	75-85	CXADR pseudogene 1	Homo sapiens	45-48
32851343-4	2020	Case presentation: A 55-month-old boy with stage IV HR-NB received 4th-generation CAR-T cells that target disialoganglioside GD2, as consolidation maintenance treatment after intensive chemotherapy, surgery, and autologous stem-cell transplantation.	ganglioside, GD2	106-128	CXADR pseudogene 1	Homo sapiens	82-85
32202166-2	2020	Phenobarbital, a well-known liver cancer promoter, has been found to promote hepatocyte proliferation via CAR activation.	Phenobarbital	0-13	CXADR pseudogene 1	Homo sapiens	106-109
32202166-4	2020	In addition, it is believed that CAR-mediated liver carcinogenesis shows a species difference; phenobarbital treatment induces hepatocyte proliferation and liver cancer in rodents but not in humans.	Phenobarbital	95-108	CXADR pseudogene 1	Homo sapiens	33-36
31915758-1	2020	The direct photocatalyzed para-selective CAr-H difluoroalkylation of aromatic aldehyde derivatives has been accomplished using a newly explored catalytic system.	Aldehydes	69-86	CXADR pseudogene 1	Homo sapiens	41-44
32101552-10	2020	PBDEs regulated overlapping pathways with PXR and CAR such as protein ubiqutination pathway and peroxisome proliferator-activated receptor alpha-retinoid X receptor alpha (PPARalpha-RXRalpha) activation but also regulate distinctive pathways involved in intermediary metabolism.	Halogenated Diphenyl Ethers	0-5	CXADR pseudogene 1	Homo sapiens	50-53
32101552-12	2020	In conclusion, we provide strong evidence that PBDEs regulate both PCGs and lncRNAs in a PXR/CAR ligand-dependent and independent manner.	Halogenated Diphenyl Ethers	47-52	CXADR pseudogene 1	Homo sapiens	93-96
31970380-7	2020	The dependence of LP on the reducing power of phenols coincided with the Marcus theory plot for the rate of electron transfer from phenols to the radical cation beta-CAR + as a primary oxidative product, suggesting that the plant phenol regeneration of beta-CAR plays an important role in stabilizing the GUV membranes, as further supported by the involvement of CAR + and the distinct shortening of its lifetime as shown by transient absorption spectroscopy.	Phenols	46-53	CXADR pseudogene 1	Homo sapiens	166-169
31970380-7	2020	The dependence of LP on the reducing power of phenols coincided with the Marcus theory plot for the rate of electron transfer from phenols to the radical cation beta-CAR + as a primary oxidative product, suggesting that the plant phenol regeneration of beta-CAR plays an important role in stabilizing the GUV membranes, as further supported by the involvement of CAR + and the distinct shortening of its lifetime as shown by transient absorption spectroscopy.	Phenols	131-138	CXADR pseudogene 1	Homo sapiens	166-169
31970380-7	2020	The dependence of LP on the reducing power of phenols coincided with the Marcus theory plot for the rate of electron transfer from phenols to the radical cation beta-CAR + as a primary oxidative product, suggesting that the plant phenol regeneration of beta-CAR plays an important role in stabilizing the GUV membranes, as further supported by the involvement of CAR + and the distinct shortening of its lifetime as shown by transient absorption spectroscopy.	Phenol	46-52	CXADR pseudogene 1	Homo sapiens	166-169
31915758-2	2020	In addition, when using para-substituted benzaldehydes as substrates, ortho-selective CAr-H difluoroalkylation was also accomplished.	Benzaldehydes	41-54	CXADR pseudogene 1	Homo sapiens	86-89
31512813-8	2020	Subgroup analyses further manifested that EC patients with higher CAR had worse OS.	Osmium	80-82	CXADR pseudogene 1	Homo sapiens	66-69
33136521-8	2020	This work demonstrates that the CAR-J reporter-cell assay can be applied to predict the profile of TCRL-TCBs without the need to produce each candidate in the final TCB format.	tcrl-tcbs	99-108	CXADR pseudogene 1	Homo sapiens	32-35
33136521-8	2020	This work demonstrates that the CAR-J reporter-cell assay can be applied to predict the profile of TCRL-TCBs without the need to produce each candidate in the final TCB format.	tcb	104-107	CXADR pseudogene 1	Homo sapiens	32-35
30293924-10	2019	CONCLUSION: The CAR may be a useful inflammation-based risk score to predict AKI development in STEMI patients treated with pPCI.	ppci	124-128	CXADR pseudogene 1	Homo sapiens	16-19
32163385-4	2020	Specifically, CD19-specific CAR-T cell products (Kymriah and Yescarta) have been highly effective against B cell lymphomas and leukemias, whereas administering oncolytic viruses resulted in pronounced responses in melanoma (Imlygic and Rigvir) and nasopharyngeal carcinoma (Oncorine) patients.	oncorine	274-282	CXADR pseudogene 1	Homo sapiens	28-31
31644587-6	2019	High pretreatment CAR was associated with worse OS (pooled HR: 2.14, 95% CI = 1.64-2.79, p < 0.001) and DFS/PFS (pooled HR: 1.75, 95% CI: 1.31-2.35, P < 0.001).	1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	108-111	CXADR pseudogene 1	Homo sapiens	18-21
33425471-0	2019	Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.	axicabtagene	0-12	CXADR pseudogene 1	Homo sapiens	48-51
33425471-0	2019	Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.	ciloleucel	13-23	CXADR pseudogene 1	Homo sapiens	48-51
30703466-4	2019	Two hierarchical logistic regressions, one including the TSST response and one including the CAR as predictor variables, suggest that cortisol reactivity, social support from the baby"s father, and neuroticism contribute to depressive symptoms, controlling for GA (both p < .01).	Hydrocortisone	134-142	CXADR pseudogene 1	Homo sapiens	93-96
31017141-0	2019	Ruthenium-catalyzed ortho-selective CAr-H amination of heteroaryl arenes with di-tert-butyldiaziridinone.	Ruthenium	0-9	CXADR pseudogene 1	Homo sapiens	36-39
31361500-5	2019	Carbamazepine induced the mRNA expressions of CAR, ABCB1, and ABCC2 but did not elevate protein abundance.	Carbamazepine	0-13	CXADR pseudogene 1	Homo sapiens	46-49
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	bpz	99-102	CXADR pseudogene 1	Homo sapiens	157-160
31195007-12	2019	The ten remaining NRs, namely, ERRgamma, ERbeta, ERalpha, CAR, GR, PXR, PR, AR, LXRbeta, and LXRalpha, showed distinctly strong binding to some bisphenols in this order, being likely to have consequential endocrine-disruption effects.	bis(4-hydroxyphenyl)sulfone	144-154	CXADR pseudogene 1	Homo sapiens	58-61
30848264-2	2019	But whether hepatic drug-metabolizing enzymes and their regulatory nuclear receptors including pregnane PXR and constitutive androstane CAR binding with retinoid receptor RXR as a heterodimer are involved in the DBDCT-mediated regulation of CYP3A remains unclear.	androstane	125-135	CXADR pseudogene 1	Homo sapiens	136-139
31321805-11	2019	To conclude, CAR-T therapy bridging to allo-HSCT is a safe and effective therapeutic strategy for r/r B-ALL patients, and may prolong their EFS and RFS, especially when they have high pre-infusion BM-FCM-MRD or poor prognostic markers.	bm-fcm	197-203	CXADR pseudogene 1	Homo sapiens	13-16
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	bisphenol A	34-37	CXADR pseudogene 1	Homo sapiens	157-160
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	bis(4-hydroxyphenyl)sulfone	54-64	CXADR pseudogene 1	Homo sapiens	157-160
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	4-boronophenylalanine-fructose	68-72	CXADR pseudogene 1	Homo sapiens	157-160
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	bpap	74-78	CXADR pseudogene 1	Homo sapiens	157-160
31195007-5	2019	The results clearly revealed that BPA and the NextGen bisphenols of BPAF, BPAP, BPB, BPC, BPE, and BPZ were highly potent against one or more of NRs such as CAR, ERalpha, ERbeta, ERRgamma, and GR, with IC50 values of 3.3-73 nM.	bpb	80-83	CXADR pseudogene 1	Homo sapiens	157-160
33981978-5	2019	In the prospective arm, the postoperative endoscopic scores were significantly higher in the DP-CAR group (45%) than in the DP group (11%) (p < .0007) despite no difference in the GIQLI score.	Dipyridamole	93-95	CXADR pseudogene 1	Homo sapiens	96-99
33981978-8	2019	Despite the high IG rate, gastric arterial flow volume was almost equally maintained in DP-CAR patients with or without IG compared with the DP group.	Dipyridamole	88-90	CXADR pseudogene 1	Homo sapiens	91-94
31067732-6	2019	In vitro drug dissolution study showed that both MSN and MCN-COOH could improve the dissolution rate of CAR compared with the micronized CAR.	Carbonic Acid	61-65	CXADR pseudogene 1	Homo sapiens	104-107
31067732-7	2019	In comparison to MSN, MCN-COOH displayed a slightly slower dissolution profile, which may be ascribed to the strong interaction between MCN-COOH and CAR.	mcn	22-25	CXADR pseudogene 1	Homo sapiens	136-152
31067732-4	2019	Carvedilol (CAR), a Bio-pharmaceutic Classification System (BCS) class II drug, was loaded in the MSN and MCN by the solvent adsorption method and solvent evaporation method with different carrier-drug ratios.	Carvedilol	0-10	CXADR pseudogene 1	Homo sapiens	12-15
31067732-5	2019	The carboxylated MCN (MCN-COOH) had a higher LE for CAR than MSN for both the two loading methods due to the strong adsorption effect and pi-pi stacking force with CAR.	Carbonic Acid	26-30	CXADR pseudogene 1	Homo sapiens	52-55
31067732-5	2019	The carboxylated MCN (MCN-COOH) had a higher LE for CAR than MSN for both the two loading methods due to the strong adsorption effect and pi-pi stacking force with CAR.	Carbonic Acid	26-30	CXADR pseudogene 1	Homo sapiens	164-167
31067732-7	2019	In comparison to MSN, MCN-COOH displayed a slightly slower dissolution profile, which may be ascribed to the strong interaction between MCN-COOH and CAR.	Carbonic Acid	26-30	CXADR pseudogene 1	Homo sapiens	136-152
31017141-0	2019	Ruthenium-catalyzed ortho-selective CAr-H amination of heteroaryl arenes with di-tert-butyldiaziridinone.	heteroaryl arenes	55-72	CXADR pseudogene 1	Homo sapiens	36-39
31067732-6	2019	In vitro drug dissolution study showed that both MSN and MCN-COOH could improve the dissolution rate of CAR compared with the micronized CAR.	mannostatin A	49-52	CXADR pseudogene 1	Homo sapiens	104-107
31067732-6	2019	In vitro drug dissolution study showed that both MSN and MCN-COOH could improve the dissolution rate of CAR compared with the micronized CAR.	mcn	57-60	CXADR pseudogene 1	Homo sapiens	104-107
31017141-0	2019	Ruthenium-catalyzed ortho-selective CAr-H amination of heteroaryl arenes with di-tert-butyldiaziridinone.	di-tert-butyldiaziridinone	78-104	CXADR pseudogene 1	Homo sapiens	36-39
31017141-1	2019	Application of an oxidative amination reagent (di-tert-butyldiaziridinone) to the Ru3(CO)12-catalyzed ortho-selective CAr-H amination reaction is described.	di-tert-butyldiaziridinone	47-73	CXADR pseudogene 1	Homo sapiens	118-121
31017141-1	2019	Application of an oxidative amination reagent (di-tert-butyldiaziridinone) to the Ru3(CO)12-catalyzed ortho-selective CAr-H amination reaction is described.	Ru3(CO)12	82-91	CXADR pseudogene 1	Homo sapiens	118-121
30558004-5	2018	Subgroup analysis showed that high level of CAR predicted poor OS in patients with lung cancer though multivariate analyses on 1092 participants (HR: 1.63; 95% CI: 1.24-2.51; P &lt; .001) and the heterogeneity decreased to 45.4%.	Osmium	63-65	CXADR pseudogene 1	Homo sapiens	44-47
31206263-1	2019	Alcohol intoxication during car driving represents a well-recognized danger and is responsible for numerous accidents leading to premature death or infirmities.	Alcohols	0-7	CXADR pseudogene 1	Homo sapiens	28-31
31206263-2	2019	The objectives of this article are to describe some epidemiological data about driving under alcohol influence and associated car accidents, to remind which alcohol blood concentrations are acceptable from a legal point of view, to analyse the acute effects of alcohol on cortical function that could alter driving capacities and, finally, to consider some conditions that may reduce or increase the effects of alcohol on the performances during car driving.	Alcohols	93-100	CXADR pseudogene 1	Homo sapiens	126-129
30938714-8	2019	Ex vivo expansion of T-cells and proportions of CD4+/CD8+ CAR T-cells with CD62L+CD127+ immunophenotype were significantly greater in patients on ibrutinib at leukapheresis.	ibrutinib	146-155	CXADR pseudogene 1	Homo sapiens	58-61
31372204-4	2019	Given his aggressive disease, combined with the time needed to generate CAR-T cells, a multidisciplinary team recommended to treat our patient with liposomal vincristine in combination with rituximab as a bridge therapy.	Vincristine	158-169	CXADR pseudogene 1	Homo sapiens	72-75
31372204-7	2019	This case looks to illustrate the use of liposomal vincristine in combination with immunotherapy in a novel setting bridging highly selected patients with active and refractory lymphoma prior to CAR-T.	Vincristine	51-62	CXADR pseudogene 1	Homo sapiens	195-198
30772656-5	2019	The consensus of the clinicians attending the meeting was that CAR T-cells, T-cell engagers and antibody drug conjugates (excluding those with a vinca alkaloid-like drug) presently have the greatest probability of providing benefit in relapse in view of their mechanism of action.	Vinca Alkaloids	145-159	CXADR pseudogene 1	Homo sapiens	63-66
31052261-3	2019	CAR-T cells expanded to a much lower extent in 1% oxygen than in 18% oxygen.	Oxygen	50-56	CXADR pseudogene 1	Homo sapiens	0-3
31052261-6	2019	Atmospheric and hypoxic CAR-T cells exhibited comparable cytolytic activity and PD-1 upregulation; however, cytokine production and granzyme B release were greatly decreased in 1% oxygen, even when the CAR-T cells were generated in atmospheric culture.	Oxygen	180-186	CXADR pseudogene 1	Homo sapiens	24-27
31052261-6	2019	Atmospheric and hypoxic CAR-T cells exhibited comparable cytolytic activity and PD-1 upregulation; however, cytokine production and granzyme B release were greatly decreased in 1% oxygen, even when the CAR-T cells were generated in atmospheric culture.	Oxygen	180-186	CXADR pseudogene 1	Homo sapiens	202-205
31052261-7	2019	Together, these data show that at solid tumor oxygen levels, CAR-T cells are impaired in expansion, differentiation and cytokine production.	Oxygen	46-52	CXADR pseudogene 1	Homo sapiens	61-64
30841620-8	2019	In conclusion, cisplatin synergistically increased the tumor-killing of CRAd by (1) increasing CRAd transduction via enhanced CAR expression and (2) increasing p53 dependent or independent apoptosis of lung cancer cell lines.	Cisplatin	15-24	CXADR pseudogene 1	Homo sapiens	126-129
31159144-7	2019	The results indicated that PCBs 20, 52 and 56 reduced the expression of AhR, while elevated that of CAR and PXR, with thresholds at low micromolar concentrations.	Polychlorinated Biphenyls	27-31	CXADR pseudogene 1	Homo sapiens	100-103
31815118-2	2019	Key transcription factors that recognize xenobiotics or xenobiotic-induced stress such as reactive oxygen species (ROS), include AhR, PXR, CAR, MTF, Nrf2, NF-kappaB, and AP-1.	Oxygen	99-105	CXADR pseudogene 1	Homo sapiens	139-142
29665350-6	2018	Thus, in the present study PA-dependent activation of a comprehensive panel of nuclear receptors (PPARs, LXRalpha, RARalpha, RXRalpha, FXR, CAR, PXR, ERalpha/beta) was investigated using GAL4/UAS-based transactivation reporter gene assays.	Pyrrolizidine Alkaloids	27-29	CXADR pseudogene 1	Homo sapiens	140-143
32254653-0	2018	Two-photon fluorescent polydopamine nanodots for CAR-T cell function verification and tumor cell/tissue detection.	polydopamine	23-35	CXADR pseudogene 1	Homo sapiens	49-52
32254653-7	2018	After ingestion of OPDA nanodots, Raji cells can be used to verify CAR-T cell lethality and efficiency by visualization through fluorescence.	1,2-diaminobenzene	19-23	CXADR pseudogene 1	Homo sapiens	67-70
30524966-6	2018	In overnight cytokine release assays in which CAR T cells were challenged with the CD33+ tumor cells HL-60, MOLM-14 and KG-1a, CAR33VH elicited IFN-gamma, TNF-alpha and IL-2.	car33vh	127-134	CXADR pseudogene 1	Homo sapiens	46-49
28495613-6	2017	This finding supports the hypothesis THF-induced carcinogenicity is likely mediated via CAR activation that has limited, if any, relevance to humans.	tetrahydrofuran	37-40	CXADR pseudogene 1	Homo sapiens	88-91
29503584-8	2018	Patients with high CAR values had significantly poorer DMFS than those with low CAR in univariate and multivariate analyses before propensity score matching.	dmfs	55-59	CXADR pseudogene 1	Homo sapiens	19-22
29301444-4	2018	Another chemically diverse group of xenobiotics including phenobarbital, DDT, can activate the nuclear receptor CAR and in some cases estrogen receptors ESR1 and ESR2.	Phenobarbital	58-71	CXADR pseudogene 1	Homo sapiens	112-115
29301444-4	2018	Another chemically diverse group of xenobiotics including phenobarbital, DDT, can activate the nuclear receptor CAR and in some cases estrogen receptors ESR1 and ESR2.	DDT	73-76	CXADR pseudogene 1	Homo sapiens	112-115
29215181-1	2018	A highly para-selective CAr -H difluoromethylation of ketoxime ethers under ruthenium catalysis has been developed.	ketoxime ethers	54-69	CXADR pseudogene 1	Homo sapiens	24-27
29215181-1	2018	A highly para-selective CAr -H difluoromethylation of ketoxime ethers under ruthenium catalysis has been developed.	Ruthenium	76-85	CXADR pseudogene 1	Homo sapiens	24-27
28223183-10	2017	The fingerprint sequences broaden our understanding of the amino acids that might be essential for the reduction of organic acids to the corresponding aldehydes in CAR proteins.	organic acids	116-129	CXADR pseudogene 1	Homo sapiens	164-167
28223183-10	2017	The fingerprint sequences broaden our understanding of the amino acids that might be essential for the reduction of organic acids to the corresponding aldehydes in CAR proteins.	Aldehydes	151-160	CXADR pseudogene 1	Homo sapiens	164-167
30029731-5	2018	DHEA activates peroxisome proliferator-activated receptor (PPARalpha) and CAR by a mechanism apparently involving PP2A, a protein phosphatase dephosphorylating PPARalpha and CAR to activate their transcriptional activity.	Dehydroepiandrosterone	0-4	CXADR pseudogene 1	Homo sapiens	74-77
30029731-5	2018	DHEA activates peroxisome proliferator-activated receptor (PPARalpha) and CAR by a mechanism apparently involving PP2A, a protein phosphatase dephosphorylating PPARalpha and CAR to activate their transcriptional activity.	Dehydroepiandrosterone	0-4	CXADR pseudogene 1	Homo sapiens	174-177
28920616-0	2017	Vitamin C protects piglet liver against zearalenone-induced oxidative stress by modulating expression of nuclear receptors PXR and CAR and their target genes.	Ascorbic Acid	0-9	CXADR pseudogene 1	Homo sapiens	131-134
28920616-0	2017	Vitamin C protects piglet liver against zearalenone-induced oxidative stress by modulating expression of nuclear receptors PXR and CAR and their target genes.	Zearalenone	40-51	CXADR pseudogene 1	Homo sapiens	131-134
28849826-3	2017	In this study, we designed a novel folic acid-PEG-conjugated p-phosphonated calix[4]arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5 : 1, mol : mol) to utilize their potential synergistic effect against OC cells.	Folic Acid	35-45	CXADR pseudogene 1	Homo sapiens	179-182
28849826-3	2017	In this study, we designed a novel folic acid-PEG-conjugated p-phosphonated calix[4]arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5 : 1, mol : mol) to utilize their potential synergistic effect against OC cells.	Polyethylene Glycols	46-49	CXADR pseudogene 1	Homo sapiens	179-182
28849826-3	2017	In this study, we designed a novel folic acid-PEG-conjugated p-phosphonated calix[4]arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5 : 1, mol : mol) to utilize their potential synergistic effect against OC cells.	calix[4]	76-84	CXADR pseudogene 1	Homo sapiens	179-182
28849826-3	2017	In this study, we designed a novel folic acid-PEG-conjugated p-phosphonated calix[4]arene nanoparticle (Fp-PCN) for the simultaneous delivery of paclitaxel (PAC) and carboplatin (CAR) at an optimal ratio (5 : 1, mol : mol) to utilize their potential synergistic effect against OC cells.	Pregnenolone Carbonitrile	107-110	CXADR pseudogene 1	Homo sapiens	179-182
28511045-5	2017	Hierarchical linear models, adjusted for duration of time on testosterone therapy, body mass index, steroid-related medication use, mean awakening time, and CAR, confirmed that elevated diurnal cortisol levels at awakening were associated with transition-specific social stressors including experiencing Transitioning-identity stress, frequent Coming Out stress, and Gender-specific Public Bathroom stress.	Hydrocortisone	194-202	CXADR pseudogene 1	Homo sapiens	157-160
27706371-4	2016	The distribution of betaS haplotypes among Brazilian populations showed a predominance of the CAR haplotype.	betas	20-25	CXADR pseudogene 1	Homo sapiens	94-97
28592881-8	2017	CAR was an independent prognostic factor for OS in the Cox regression model (HR, 1.623; 95% CI, 1.093-2.410; P = 0.016).	Osmium	45-47	CXADR pseudogene 1	Homo sapiens	0-3
27838849-3	2016	Stimulation of the Ca2+-sensing receptor CaR, a pleiotropic G protein-coupled receptor, activates both Gq/11, which decreases PIP2, and phosphatidylinositol 4-kinase (PI-4-K), which, conversely, increases PIP2.	Phosphatidylinositol 4,5-Diphosphate	126-130	CXADR pseudogene 1	Homo sapiens	41-44
27838849-3	2016	Stimulation of the Ca2+-sensing receptor CaR, a pleiotropic G protein-coupled receptor, activates both Gq/11, which decreases PIP2, and phosphatidylinositol 4-kinase (PI-4-K), which, conversely, increases PIP2.	Phosphatidylinositol 4,5-Diphosphate	205-209	CXADR pseudogene 1	Homo sapiens	41-44
27838849-4	2016	How membrane PIP2 levels are regulated by CaR activation and whether these changes modulate inward rectifier K+ are unknown.	Phosphatidylinositol 4,5-Diphosphate	13-17	CXADR pseudogene 1	Homo sapiens	42-45
27838849-6	2016	Moreover, using the fluorescent PIP2 reporter tubby-R332H-cYFP to monitor PIP2 levels, we found that CaR activation in HEK293T cells increased membrane PIP2 concentrations.	Phosphatidylinositol 4,5-Diphosphate	32-36	CXADR pseudogene 1	Homo sapiens	101-104
27838849-6	2016	Moreover, using the fluorescent PIP2 reporter tubby-R332H-cYFP to monitor PIP2 levels, we found that CaR activation in HEK293T cells increased membrane PIP2 concentrations.	Phosphatidylinositol 4,5-Diphosphate	74-78	CXADR pseudogene 1	Homo sapiens	101-104
27838849-7	2016	Pharmacological studies showed that both phospholipase C (PLC) and PI-4-K are activated by CaR stimulation with the latter played a dominant role in regulating membrane PIP2 and, thus, Kir currents.	Phosphatidylinositol 4,5-Diphosphate	169-173	CXADR pseudogene 1	Homo sapiens	91-94
27838849-8	2016	These results provide the first direct evidence that CaR activation upregulates currents through inward rectifier K+ channels by accelerating PIP2 synthesis.	Phosphatidylinositol 4,5-Diphosphate	142-146	CXADR pseudogene 1	Homo sapiens	53-56
28128493-0	2017	NHC-Organocatalyzed CAr -O Bond Cleavage: Mild Access to 2-Hydroxybenzophenones.	ortho-hydroxybenzophenone	57-79	CXADR pseudogene 1	Homo sapiens	20-23
28128493-2	2017	The developed method includes CAr -O, CAr -S, or CAr -N bond cleavage for the formation of a CAr -C bond and enables access to 2-hydroxybenzophenones, an important structural motif that is present in several bioactive natural products.	ortho-hydroxybenzophenone	127-149	CXADR pseudogene 1	Homo sapiens	30-33
28128493-2	2017	The developed method includes CAr -O, CAr -S, or CAr -N bond cleavage for the formation of a CAr -C bond and enables access to 2-hydroxybenzophenones, an important structural motif that is present in several bioactive natural products.	ortho-hydroxybenzophenone	127-149	CXADR pseudogene 1	Homo sapiens	38-41
28128493-2	2017	The developed method includes CAr -O, CAr -S, or CAr -N bond cleavage for the formation of a CAr -C bond and enables access to 2-hydroxybenzophenones, an important structural motif that is present in several bioactive natural products.	ortho-hydroxybenzophenone	127-149	CXADR pseudogene 1	Homo sapiens	38-41
28128493-2	2017	The developed method includes CAr -O, CAr -S, or CAr -N bond cleavage for the formation of a CAr -C bond and enables access to 2-hydroxybenzophenones, an important structural motif that is present in several bioactive natural products.	ortho-hydroxybenzophenone	127-149	CXADR pseudogene 1	Homo sapiens	38-41
27181121-0	2016	Meta-Selective CAr-H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy.	arenes	34-40	CXADR pseudogene 1	Homo sapiens	15-18
27538710-12	2016	We observed similarities in gene expression and hepatic steatosis assays; however, hit data for TCS were more concordant with the hypothesized CAR/PXR activity of TCS from rodent and human in vitro studies.	Triclosan	163-166	CXADR pseudogene 1	Homo sapiens	143-146
27181121-0	2016	Meta-Selective CAr-H Nitration of Arenes through a Ru3(CO)12-Catalyzed Ortho-Metalation Strategy.	Ru3(CO)12	51-60	CXADR pseudogene 1	Homo sapiens	15-18
27181121-1	2016	The first example of transition metal-catalyzed meta-selective CAr-H nitration of arenes is described.	Metals	32-37	CXADR pseudogene 1	Homo sapiens	63-66
27181121-1	2016	The first example of transition metal-catalyzed meta-selective CAr-H nitration of arenes is described.	arenes	82-88	CXADR pseudogene 1	Homo sapiens	63-66
27181121-3	2016	Mechanism studies have demonstrated the formation of a new 18e-octahedral ruthenium species as a key ortho-CAr-H metalated intermediate, which may be responsible for the subsequent meta-selective electrophilic aromatic substitution (SEAr).	18e-octahedral ruthenium species	59-91	CXADR pseudogene 1	Homo sapiens	107-110
27122297-2	2016	This study was designed to compare the properties of collagen-chitosan porous scaffolds cross-linked with gamma-irradiation and carbodiimide (CAR) for the first time.	Carbodiimides	128-140	CXADR pseudogene 1	Homo sapiens	142-145
27092941-6	2016	Finally, 4-ipomeanol efficiently induced apoptosis in primary T cells that co-express mutant CYP4B1 and the divergently located MACS selection and CAR genes.	4-ipomeanol	9-20	CXADR pseudogene 1	Homo sapiens	147-150
24819614-8	2014	We also found that U0126 up-regulates the mRNA expression of the nuclear receptors HNF4alpha, CAR, VDR and PXR but abolishes small heterodimer partner (SHP) corepressor expression in HepG2 cells.	U 0126	19-24	CXADR pseudogene 1	Homo sapiens	94-97
26899675-6	2016	Bisulfite sequencing analysis demonstrated that promoter hypermethylation of CAR and PXR was associated with diminished transcriptional activity in hPSC-HLCs.	hydrogen sulfite	0-9	CXADR pseudogene 1	Homo sapiens	77-80
26162669-3	2015	The HS-SPME parameters were optimized as follows: selection of CAR/PDMS fiber, 0.5% 2-(bromomethyl)naphthalene, 250 mg/L 15-crown-5-ether as a phase transfer catalyst, extraction and derivatization temperature of 95  C, heating time of 20 min and pH of 7.0.	Hydrogen	4-6	CXADR pseudogene 1	Homo sapiens	63-66
26808364-8	2016	Stepwise regression analysis for all subjects in the elderly and control groups showed that the CDFVA predicted the CAR most significantly among the clinical factors evaluated.	cdfva	96-101	CXADR pseudogene 1	Homo sapiens	116-119
27665777-0	2016	Metabolism of methiocarb and carbaryl by rat and human livers and plasma, and effect on their PXR, CAR and PPARalpha activities.	Methiocarb	14-24	CXADR pseudogene 1	Homo sapiens	99-102
25600905-7	2015	Serum free L-carnitine concentration increased significantly after interventions in CAR and CAR+EXR groups.	Carnitine	11-22	CXADR pseudogene 1	Homo sapiens	84-87
25600905-7	2015	Serum free L-carnitine concentration increased significantly after interventions in CAR and CAR+EXR groups.	Carnitine	11-22	CXADR pseudogene 1	Homo sapiens	92-99
25600905-9	2015	L-carnitine supplementation plus aerobic training led to significant decrease of serum Hs-CRP levels in CAR+EXR group compared with baseline values.	Carnitine	0-11	CXADR pseudogene 1	Homo sapiens	104-111
25687096-2	2015	The cross-linking reaction of iota-carrageenan (iCAR) and kappa-carrageenan (kCAR) with glutaraldehyde (GLA) at different concentrations (2.5% or 5% (w/w), mass of GLA per mass of CAR) was studied (iCAR/GLA2.5, iCAR/GLA5, kCAR/GLA2.5, kCAR/GLA5).	Carrageenan	30-46	CXADR pseudogene 1	Homo sapiens	49-52
25661872-3	2015	These responses are strictly limited and are tightly linked, since beta-catenin is activated in nearly all of the CAR-dependent tumours generated by the tumour promoter phenobarbital.	Phenobarbital	169-182	CXADR pseudogene 1	Homo sapiens	114-117
23607986-9	2013	The MoA data available by the time of the carcinogenicity finding supported the conclusion that the carcinogenic potential of sulfoxaflor was due to CAR/PXR nuclear receptor activation with subsequent hepatocellular proliferation.	sulfoxaflor	126-137	CXADR pseudogene 1	Homo sapiens	149-152
25049283-4	2014	Primary human NKT cells were engineered to express a CAR against the GD2 ganglioside (CAR.GD2), which is highly expressed by neuroblastoma (NB).	ganglioside, GD2	69-84	CXADR pseudogene 1	Homo sapiens	86-93
24939615-1	2014	Poly(ethylene glycol)-b-poly(caprolactone) (PEG-b-PCL) micelles dually loaded with both pheophorbide a (PhA) as a photosensitizer and beta-carotene (CAR) as a singlet oxygen ((1)O2) scavenger were designed to control photodynamic therapy (PDT) activity in cancer treatment.	poly(ethylene glycol)-b-poly(caprolactone)	0-42	CXADR pseudogene 1	Homo sapiens	134-153
24939615-1	2014	Poly(ethylene glycol)-b-poly(caprolactone) (PEG-b-PCL) micelles dually loaded with both pheophorbide a (PhA) as a photosensitizer and beta-carotene (CAR) as a singlet oxygen ((1)O2) scavenger were designed to control photodynamic therapy (PDT) activity in cancer treatment.	peg-b-pcl	44-53	CXADR pseudogene 1	Homo sapiens	134-153
22820246-2	2012	For examples: (i) bilirubin is solely conjugated by UGT1A1 and activates its transcription factors Ah receptor, PXR and CAR.	Bilirubin	18-27	CXADR pseudogene 1	Homo sapiens	120-123
23238077-5	2013	In addition, 293 cells treated with dioscin displayed decreased mRNA levels for adenovirus receptor (CAR).	dioscin	36-43	CXADR pseudogene 1	Homo sapiens	101-104
23238077-6	2013	Over expression of CAR in 293 cells pretreated with dioscin restored the infectivity of adenovirus.	dioscin	52-59	CXADR pseudogene 1	Homo sapiens	19-22
23360526-11	2013	Conjugation of the CD19sIg1-4 fusion protein to Alexa Fluor 488 allowed specific and sensitive staining of anti-CD19 CAR-bearing cells for flow cytometry assays, detecting as low as 0.5% of CAR-modified primary cells with minimal background staining.	alexa fluor 488	48-63	CXADR pseudogene 1	Homo sapiens	117-120
23360526-11	2013	Conjugation of the CD19sIg1-4 fusion protein to Alexa Fluor 488 allowed specific and sensitive staining of anti-CD19 CAR-bearing cells for flow cytometry assays, detecting as low as 0.5% of CAR-modified primary cells with minimal background staining.	alexa fluor 488	48-63	CXADR pseudogene 1	Homo sapiens	190-193
23086484-3	2012	Therefore, according to different R&amp;D theories between Chinese and Western medicine, we put forward a new strategy in drug design of Chinese medicine, which focuses on "combination-activity relationship (CAR)", taking prescription discovery, component identification and formula optimization as three key points to identify the drugs of high efficacy and low toxicity.	O-beta-ribosyl(1''--2')adenosine-5''-phosphate	34-39	CXADR pseudogene 1	Homo sapiens	172-213
22664347-3	2012	To better understand the biological actions of non-coplanar PCBs, we have undertaken a systematic analysis of their ability to activate PXR and CAR-mediated effects.	Polychlorinated Biphenyls	60-64	CXADR pseudogene 1	Homo sapiens	144-147
22664347-5	2012	Several of the non-coplanar PCBs directly activated PXR and CAR, whilst the coplanar PCB77 did not.	Polychlorinated Biphenyls	28-32	CXADR pseudogene 1	Homo sapiens	60-63
22664347-4	2012	Cells were exposed to a range of non-coplanar PCBs (99, 138, 153, 180 and 194), or the coplanar PCB77: Direct activation of PXR and CAR was measured using a mammalian receptor activation assay in human liver cells, with rifampicin and CITCO used as positive controls ligands for PXR and CAR, respectively; activation of target gene expression was examined using reporter gene plasmids for CYP3A4 and MDR1 transfected into liver, intestine and lung cell lines.	3,4,3',4'-tetrachlorobiphenyl	96-101	CXADR pseudogene 1	Homo sapiens	132-135
22664347-6	2012	Non-coplanar PCBs were also able to activate PXR/CAR target gene expression in a substitution- and tissue-specific manner.	Polychlorinated Biphenyls	13-17	CXADR pseudogene 1	Homo sapiens	49-52
22664347-7	2012	Non-coplanar PCBs act as direct activators for the nuclear receptors PXR and CAR, and are able to elicit transcriptional activation of target genes in a substitution- and tissue-dependent manner.	Polychlorinated Biphenyls	13-17	CXADR pseudogene 1	Homo sapiens	77-80
21451576-4	2011	Given that T cells modified with SB100X and SB11 integrate on average one copy of the CAR transposon in each T-cell genome, the improved transposition mediated by SB100X apparently leads to an augmented founder effect of electroporated T cells with durable integration of CAR.	sb100x	33-39	CXADR pseudogene 1	Homo sapiens	86-89
22664347-8	2012	Chronic activation of PXR/CAR is linked to adverse effects and must be included in any risk assessment of PCBs.	Polychlorinated Biphenyls	106-110	CXADR pseudogene 1	Homo sapiens	26-29
22897076-1	2012	Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use.	Tigecycline	0-11	CXADR pseudogene 1	Homo sapiens	22-25
22897076-1	2012	Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use.	tygacyl	31-38	CXADR pseudogene 1	Homo sapiens	22-25
22897076-1	2012	Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use.	CL 331002	53-66	CXADR pseudogene 1	Homo sapiens	22-25
23284987-5	2012	We found that MPs derived from CHO cells (MP-donor cells) constitutively expressing CAR (MP-CAR) or CD46 (MP-CD46) were able to transfer CAR and CD46 to target CHO cells, and conferred selective permissiveness to HAdV5 and HAdV35.	CAV protocol	31-34	CXADR pseudogene 1	Homo sapiens	84-87
23284987-5	2012	We found that MPs derived from CHO cells (MP-donor cells) constitutively expressing CAR (MP-CAR) or CD46 (MP-CD46) were able to transfer CAR and CD46 to target CHO cells, and conferred selective permissiveness to HAdV5 and HAdV35.	CAV protocol	31-34	CXADR pseudogene 1	Homo sapiens	89-95
23284987-5	2012	We found that MPs derived from CHO cells (MP-donor cells) constitutively expressing CAR (MP-CAR) or CD46 (MP-CD46) were able to transfer CAR and CD46 to target CHO cells, and conferred selective permissiveness to HAdV5 and HAdV35.	CAV protocol	31-34	CXADR pseudogene 1	Homo sapiens	92-95
21451576-4	2011	Given that T cells modified with SB100X and SB11 integrate on average one copy of the CAR transposon in each T-cell genome, the improved transposition mediated by SB100X apparently leads to an augmented founder effect of electroporated T cells with durable integration of CAR.	sb100x	33-39	CXADR pseudogene 1	Homo sapiens	272-275
21451576-5	2011	In aggregate, SB100X improves SB transposition in primary human T cells and can be titrated with an SB transposon plasmid to improve the generation of CD19-specific CAR+ T cells.	sb100x	14-20	CXADR pseudogene 1	Homo sapiens	165-168
21451576-5	2011	In aggregate, SB100X improves SB transposition in primary human T cells and can be titrated with an SB transposon plasmid to improve the generation of CD19-specific CAR+ T cells.	Antimony	14-16	CXADR pseudogene 1	Homo sapiens	165-168
21622216-6	2011	In addition to FXR, the nuclear receptors CAR and PXR function as sensors of toxic byproducts and regulator of BA homeostasis.	Bile Acids and Salts	111-113	CXADR pseudogene 1	Homo sapiens	42-45
21340433-4	2011	The results showed that different concentrations of extracellular Ca(2+) failed to increase [Ca(2+)](i), while the CaR agonist Spermine (2 mmol/L) resulted in an increase in [Ca(2+)](i) that was diminished in buffer without Ca(2+) (P&lt;0.05).	Spermine	127-135	CXADR pseudogene 1	Homo sapiens	115-118
21821919-0	2011	Polyphenols in alcoholic beverages activating constitutive androstane receptor CAR.	Polyphenols	0-11	CXADR pseudogene 1	Homo sapiens	79-82
21821919-1	2011	The constitutive androstane receptor CAR is a xenosensing nuclear receptor that can be activated by natural polyphenols such as flavonoids and catechins.	Polyphenols	108-119	CXADR pseudogene 1	Homo sapiens	37-40
21821919-1	2011	The constitutive androstane receptor CAR is a xenosensing nuclear receptor that can be activated by natural polyphenols such as flavonoids and catechins.	Flavonoids	128-138	CXADR pseudogene 1	Homo sapiens	37-40
21821919-1	2011	The constitutive androstane receptor CAR is a xenosensing nuclear receptor that can be activated by natural polyphenols such as flavonoids and catechins.	Catechin	143-152	CXADR pseudogene 1	Homo sapiens	37-40
21821919-5	2011	Since CAR regulates many genes involved in energy metabolism, the possibility exists that these polyphenols would reduce the risk of certain alcohol-induced metabolic disorders with the help of CAR.	Polyphenols	96-107	CXADR pseudogene 1	Homo sapiens	6-9
21821919-5	2011	Since CAR regulates many genes involved in energy metabolism, the possibility exists that these polyphenols would reduce the risk of certain alcohol-induced metabolic disorders with the help of CAR.	Polyphenols	96-107	CXADR pseudogene 1	Homo sapiens	194-197
21821919-5	2011	Since CAR regulates many genes involved in energy metabolism, the possibility exists that these polyphenols would reduce the risk of certain alcohol-induced metabolic disorders with the help of CAR.	Alcohols	141-148	CXADR pseudogene 1	Homo sapiens	6-9
21821919-5	2011	Since CAR regulates many genes involved in energy metabolism, the possibility exists that these polyphenols would reduce the risk of certain alcohol-induced metabolic disorders with the help of CAR.	Alcohols	141-148	CXADR pseudogene 1	Homo sapiens	194-197
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	Peroxides	19-27	CXADR pseudogene 1	Homo sapiens	79-82
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	Peroxides	19-27	CXADR pseudogene 1	Homo sapiens	95-98
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	Peroxides	19-27	CXADR pseudogene 1	Homo sapiens	95-98
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	roo	29-32	CXADR pseudogene 1	Homo sapiens	79-82
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	roo	29-32	CXADR pseudogene 1	Homo sapiens	95-98
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	roo	29-32	CXADR pseudogene 1	Homo sapiens	95-98
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	Linoleic Acid	167-180	CXADR pseudogene 1	Homo sapiens	95-98
21105679-2	2010	In the presence of peroxide (ROO( )), the reaction barrier for its addition to CAR to form ROO-CAR( ) is smaller than those for its hydrogen abstractions from CAR and linoleic acid (LAH), respectively.	Linoleic Acid	167-180	CXADR pseudogene 1	Homo sapiens	95-98
21105679-3	2010	In contrast, the reaction barriers for the O(2) additions of the carbon-centered radicals are ordered as ROO-CAR( ) &gt; CAR(-H)( ) &gt; LA( ).	Carbon	65-71	CXADR pseudogene 1	Homo sapiens	109-112
21105679-3	2010	In contrast, the reaction barriers for the O(2) additions of the carbon-centered radicals are ordered as ROO-CAR( ) &gt; CAR(-H)( ) &gt; LA( ).	Carbon	65-71	CXADR pseudogene 1	Homo sapiens	121-124
21105679-4	2010	Thus, the chain-termination function of CAR is best demonstrated by trapping the addition radical and suppressing O(2) addition.	o(2)	114-118	CXADR pseudogene 1	Homo sapiens	40-43
21105679-5	2010	For either the ROO-CAR( ) or CAR(-H)( ) radicals, beta-carotene has noticeably higher O(2) addition barriers than those of their lycopene counterparts.	beta Carotene	50-63	CXADR pseudogene 1	Homo sapiens	19-22
21105679-5	2010	For either the ROO-CAR( ) or CAR(-H)( ) radicals, beta-carotene has noticeably higher O(2) addition barriers than those of their lycopene counterparts.	beta Carotene	50-63	CXADR pseudogene 1	Homo sapiens	29-32
21105679-6	2010	The reaction barrier for the rearrangement of ROO-CAR( ) into RO( ) + epoxide is much smaller than that for the formation of cyclic ether and is comparable to that of O(2) addition.	ro( ) + epoxide	62-77	CXADR pseudogene 1	Homo sapiens	50-53
21105679-6	2010	The reaction barrier for the rearrangement of ROO-CAR( ) into RO( ) + epoxide is much smaller than that for the formation of cyclic ether and is comparable to that of O(2) addition.	Ethers, Cyclic	125-137	CXADR pseudogene 1	Homo sapiens	50-53
21105679-6	2010	The reaction barrier for the rearrangement of ROO-CAR( ) into RO( ) + epoxide is much smaller than that for the formation of cyclic ether and is comparable to that of O(2) addition.	o(2)	167-171	CXADR pseudogene 1	Homo sapiens	50-53
21287733-2	2010	METHODS: Improved immunohistochemical technique was used to detect the expression of the CAR in myocardium samples, including 22 deceased with VMC, 20 deceased with DCM and 16 control deceased.	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	143-146	CXADR pseudogene 1	Homo sapiens	89-92
21287733-4	2010	There was a prominent CAR expression in VMC group and DCM group, which were statistically significant difference compared with control group (P &lt; 0.05).	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	40-43	CXADR pseudogene 1	Homo sapiens	22-25
21287733-5	2010	CONCLUSION: The CAR expression showed significantly higher in VMC and DCM groups.	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	62-65	CXADR pseudogene 1	Homo sapiens	16-19
20488228-3	2010	Rifampicin and phenobarbital have been shown to induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR.	Rifampin	0-10	CXADR pseudogene 1	Homo sapiens	148-151
20488228-3	2010	Rifampicin and phenobarbital have been shown to induce P-gp in hepatic and intestinal cells through the activation of the nuclear receptors PXR and CAR.	Phenobarbital	15-28	CXADR pseudogene 1	Homo sapiens	148-151
19702536-5	2009	Several drug-activated nuclear receptors including CAR, PXR, VDR, and GR recognize drug responsive elements within the 5" flanking promoter region of CYP2C genes to mediate the transcriptional upregulation of these genes in response to xenobiotics and steroids.	Steroids	252-260	CXADR pseudogene 1	Homo sapiens	51-54
19957088-7	2010	Total CAR expression was upregulated in DCM.	dcm	40-43	CXADR pseudogene 1	Homo sapiens	6-9
19957088-8	2010	Triple staining on these vessels demonstrated that both CAR and CD46 were confined to the subendothelial layer in normal hearts.	triple	0-6	CXADR pseudogene 1	Homo sapiens	56-59
19957088-9	2010	The situation was clearly different in DCM, where both CAR and CD46 were expressed by endothelial cells.	dcm	39-42	CXADR pseudogene 1	Homo sapiens	55-58
19686701-0	2010	Retinoids activate RXR/CAR-mediated pathway and induce CYP3A.	Retinoids	0-9	CXADR pseudogene 1	Homo sapiens	23-26
19686701-2	2010	In this study, a panel of retinoids and carotenoids was examined to determine their effects on activation of RXR/CAR-mediated pathway and regulation of CYP3A gene expression.	Retinoids	26-35	CXADR pseudogene 1	Homo sapiens	113-116
19686701-2	2010	In this study, a panel of retinoids and carotenoids was examined to determine their effects on activation of RXR/CAR-mediated pathway and regulation of CYP3A gene expression.	Carotenoids	40-51	CXADR pseudogene 1	Homo sapiens	113-116
19686701-3	2010	Transient transfection assays of HepG2 cells revealed that five out of thirteen studied retinoids significantly induced RXRalpha/CAR-mediated activation of luciferase activity that is driven by the thymidine kinase promoter linked with a PXR binding site in the CYP3A4 gene [tk-(3A4)(3)-Luc reporter].	Retinoids	88-97	CXADR pseudogene 1	Homo sapiens	129-132
19886649-1	2009	Chain-breaking reactions against lipid peroxidation performed by carotenes, including beta-carotene (beta-CAR) and lycopene (LYC), have been studied using density functional theory.	Carotenoids	65-74	CXADR pseudogene 1	Homo sapiens	106-109
19886649-1	2009	Chain-breaking reactions against lipid peroxidation performed by carotenes, including beta-carotene (beta-CAR) and lycopene (LYC), have been studied using density functional theory.	beta Carotene	86-99	CXADR pseudogene 1	Homo sapiens	106-109
19886649-4	2009	In the case of hydrogen abstraction, the resulting carotene radical CAR(-H)(*) has a smaller O(2) affinity than the linoleic acid radical (LA(*)).	Hydrogen	15-23	CXADR pseudogene 1	Homo sapiens	68-71
19886649-4	2009	In the case of hydrogen abstraction, the resulting carotene radical CAR(-H)(*) has a smaller O(2) affinity than the linoleic acid radical (LA(*)).	Carotenoids	51-59	CXADR pseudogene 1	Homo sapiens	68-71
19886649-4	2009	In the case of hydrogen abstraction, the resulting carotene radical CAR(-H)(*) has a smaller O(2) affinity than the linoleic acid radical (LA(*)).	o(2)	93-97	CXADR pseudogene 1	Homo sapiens	68-71
19886649-4	2009	In the case of hydrogen abstraction, the resulting carotene radical CAR(-H)(*) has a smaller O(2) affinity than the linoleic acid radical (LA(*)).	linoleic acid radical	116-137	CXADR pseudogene 1	Homo sapiens	68-71
19886649-5	2009	Formation of the addition adduct radical ROO-CAR(*) is energetically favorable, and it has an even smaller tendency to react with O(2) than CAR(-H)(*).	o(2)	130-134	CXADR pseudogene 1	Homo sapiens	45-48
19886649-5	2009	Formation of the addition adduct radical ROO-CAR(*) is energetically favorable, and it has an even smaller tendency to react with O(2) than CAR(-H)(*).	o(2)	130-134	CXADR pseudogene 1	Homo sapiens	140-143
19886649-6	2009	Comparatively, ROO-beta-CAR(*) is less likely to react with O(2) than ROO-LYC(*).	o(2)	60-64	CXADR pseudogene 1	Homo sapiens	24-27
19886649-6	2009	Comparatively, ROO-beta-CAR(*) is less likely to react with O(2) than ROO-LYC(*).	Lycopene	74-77	CXADR pseudogene 1	Homo sapiens	24-27
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	Hydrogen	9-17	CXADR pseudogene 1	Homo sapiens	53-56
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	Hydrogen	9-17	CXADR pseudogene 1	Homo sapiens	72-75
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	roo(*) radical	108-122	CXADR pseudogene 1	Homo sapiens	53-56
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	roo(*) radical	108-122	CXADR pseudogene 1	Homo sapiens	72-75
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	Hydrogen	134-142	CXADR pseudogene 1	Homo sapiens	53-56
19886649-7	2009	Both the hydrogen abstraction and addition radicals (CAR(-H)(*) and ROO-CAR(*)) react readily with a second ROO(*) radical via either hydrogen abstraction or addition.	Hydrogen	134-142	CXADR pseudogene 1	Homo sapiens	72-75
19481757-7	2009	Compared with the commercial coated ones (e.g. PDMS, CW/DVB and DVB/CAR/PDMS), the carbon monolith-based fiber had advantages of faster extraction equilibrium and higher extraction capacity due to the superior pore connectivity and pore openness resulting from its bimodal porous substructure.	Carbon	83-89	CXADR pseudogene 1	Homo sapiens	68-71
20642445-3	2010	In this study, we show that ABT up-regulates expression of CYP2B6 and CYP3A4 potentially by activating nuclear receptor CAR.	1-aminobenzotriazole	28-31	CXADR pseudogene 1	Homo sapiens	120-123
20642445-6	2010	Results from luciferase reporter assays confirmed that ABT increases CYP2B6 promoter activity in CAR-expressing HepG2 cells.	1-aminobenzotriazole	55-58	CXADR pseudogene 1	Homo sapiens	97-100
20642445-7	2010	These results suggest that the use of ABT as a potentiator of pharmacological effects of rapidly-metabolized drugs is limited due to its own pharmacological actions on CYP expression as a CAR activator.	1-aminobenzotriazole	38-41	CXADR pseudogene 1	Homo sapiens	188-191
20045155-1	2010	The objective was to explore the relationship between the cortisol awakening response (CAR) and the metabolic syndrome (MetS) as defined by the National Cholesterol Education Program criteria.	Cholesterol	153-164	CXADR pseudogene 1	Homo sapiens	87-90
20483753-2	2010	In the Jurkat T cell model system, expression of a carcinoembryonic Ag-specific CD3zeta CAR (MFEzeta) resulted in an increased sensitivity of the transduced Jurkat cell to generate cytokines when stimulated through the endogenous TCR complex.	mfezeta	93-100	CXADR pseudogene 1	Homo sapiens	88-91
19686701-4	2010	All-trans retinoic acid (RA) and 9-cis RA were more effective than CAR agonist TCBOPOP in induction of the tk-(3A4)(3)-Luc reporter.	tcbopop	79-86	CXADR pseudogene 1	Homo sapiens	67-70
19686701-5	2010	Addition of retinoid and TCBOPOP further enhanced the inducibility and the induction was preferentially mediated by RXRalpha/CAR and RXRgamma/CAR heterodimer.	Retinoids	12-20	CXADR pseudogene 1	Homo sapiens	125-128
19686701-5	2010	Addition of retinoid and TCBOPOP further enhanced the inducibility and the induction was preferentially mediated by RXRalpha/CAR and RXRgamma/CAR heterodimer.	Retinoids	12-20	CXADR pseudogene 1	Homo sapiens	142-145
19686701-6	2010	Chromatin immunoprecipitation assay showed that retinoids recruit RXRalpha and CAR to the proximal ER6 and distal XREM nuclear receptor response elements of the CYP3A4 gene promoter.	Retinoids	48-57	CXADR pseudogene 1	Homo sapiens	79-82
19686701-7	2010	The experimental data demonstrate that retinoids can effectively regulate CYP3A gene expression through the RXR/CAR-mediated pathway.	Retinoids	39-48	CXADR pseudogene 1	Homo sapiens	112-115
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Omeprazole	142-152	CXADR pseudogene 1	Homo sapiens	199-202
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Rifampin	231-241	CXADR pseudogene 1	Homo sapiens	199-202
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Carbamazepine	243-255	CXADR pseudogene 1	Homo sapiens	199-202
18606396-2	2009	Two major groups of ligand-activated nuclear receptors/xenosensors evolved: the Ah receptor (activated by aryl hydrocarbons and drugs such as omeprazole) and type 2 steroid receptors such as PXR and CAR, activated by drugs such as rifampicin, carbamazepin and phenytoin.	Phenytoin	260-269	CXADR pseudogene 1	Homo sapiens	199-202
19696911-4	2008	The carboxen-polydimethylsiloxane (CAR/PDMS) fiber appears to be the most suitable for the determination of VHCs.	carboxen-polydimethylsiloxane	4-33	CXADR pseudogene 1	Homo sapiens	35-38
18442345-4	2008	RESULTS: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P&lt;0.0001) and placebo (17.7%; P&lt;0.0001).	Varenicline	35-46	CXADR pseudogene 1	Homo sapiens	9-12
18442345-4	2008	RESULTS: CAR(9-12) was greater for varenicline (44.0%) versus bupropion SR (29.7%; P&lt;0.0001) and placebo (17.7%; P&lt;0.0001).	Bupropion	62-74	CXADR pseudogene 1	Homo sapiens	9-12
18442345-5	2008	CAR(9-12) for varenicline versus placebo was not affected by age, gender, or nicotine dependence level.	Varenicline	14-25	CXADR pseudogene 1	Homo sapiens	0-3
19273385-0	2009	Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio.	Bile Acids and Salts	21-30	CXADR pseudogene 1	Homo sapiens	78-81
18634871-5	2008	Some of the effects of the bile acids are direct through the activation of specific receptors, i.e., TGR5, CAR, VDR, and FXR, while others imply modulation of the hormonal, growth factor and/or neuromediator responses, i.e., glucagon, EGF, and acetylcholine.	Bile Acids and Salts	27-37	CXADR pseudogene 1	Homo sapiens	107-110
17896511-6	2007	CONCLUSION: The prevalence of CAR expression was significantly higher in VMC and DCM patients (100% and 84% vs. 0% in control).	2-methoxy-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-4-phenyl-1H-imidazol-5-yl)phenol	73-76	CXADR pseudogene 1	Homo sapiens	30-33
18328773-4	2008	Emerging results from these more complicated, diffusion-limited systems have begun to define a role for extracellular calcium (Ca(o)(2+)) as an agonist, spurred by the cloning and characterization of a G protein-coupled receptor activated by Ca(o)(2+) (the calcium sensing receptor, CaR).	Calcium	118-125	CXADR pseudogene 1	Homo sapiens	283-286
18328773-4	2008	Emerging results from these more complicated, diffusion-limited systems have begun to define a role for extracellular calcium (Ca(o)(2+)) as an agonist, spurred by the cloning and characterization of a G protein-coupled receptor activated by Ca(o)(2+) (the calcium sensing receptor, CaR).	lime	127-132	CXADR pseudogene 1	Homo sapiens	283-286
18328773-4	2008	Emerging results from these more complicated, diffusion-limited systems have begun to define a role for extracellular calcium (Ca(o)(2+)) as an agonist, spurred by the cloning and characterization of a G protein-coupled receptor activated by Ca(o)(2+) (the calcium sensing receptor, CaR).	lime	242-247	CXADR pseudogene 1	Homo sapiens	283-286
18328773-7	2008	Ca(i)(2+) signaling-mediated Ca(o)(2+) fluctuations in interstitial spaces may integrate cell signaling responses in multicellular networks through activation of CaR.	ca(i)(2+)	0-9	CXADR pseudogene 1	Homo sapiens	162-165
18328773-7	2008	Ca(i)(2+) signaling-mediated Ca(o)(2+) fluctuations in interstitial spaces may integrate cell signaling responses in multicellular networks through activation of CaR.	lime	29-34	CXADR pseudogene 1	Homo sapiens	162-165
17892546-0	2007	HDAC inhibitor valproic acid upregulates CAR in vitro and in vivo.	Valproic Acid	15-28	CXADR pseudogene 1	Homo sapiens	41-44
17892546-3	2007	Furthermore, it has been documented that the pharmacological induction of CAR using histone deacetylase inhibitor (iHDAC) compounds is a viable strategy to enhance adenoviral mediated gene delivery to cancer cells in vitro.	ihdac	115-120	CXADR pseudogene 1	Homo sapiens	74-77
17892546-8	2007	CAR mRNA was studied using semiquantitative PCR on tumor tissue extracted from patients diagnosed with cervical cancer treated with valproic acid.	Valproic Acid	132-145	CXADR pseudogene 1	Homo sapiens	0-3
17892546-10	2007	CAR upregulation was also observed in tumor samples obtained from patients with cervical cancer treated with therapeutic doses of valproic acid.	Valproic Acid	130-143	CXADR pseudogene 1	Homo sapiens	0-3
17876342-6	2008	Interactions were observed between HNF4alpha Met49Val and CAR Pro180Pro, with patients who were wild type for both variants experiencing least docetaxel-induced neutropenia (ANOVA, P=0.030).	Docetaxel	143-152	CXADR pseudogene 1	Homo sapiens	58-61
17894517-2	2007	SWNTs were functionalized under ambient conditions with either the Knob protein domain from adenovirus serotype 12 (Ad 12 Knob) or its human cellular receptor, the CAR protein, via diimide-activated amidation.	diazene	181-188	CXADR pseudogene 1	Homo sapiens	164-167
17531955-0	2007	The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation.	strontium ranelate	50-68	CXADR pseudogene 1	Homo sapiens	30-33
17531955-3	2007	Elevating Ca(o)(2+) or Sr(2+) concentration-dependently activated the CaR in HEK-CaR but not in non-transfected cells, but the potency of Sr(2+) varied depending on the biological response tested.	lime	10-15	CXADR pseudogene 1	Homo sapiens	70-73
17531955-3	2007	Elevating Ca(o)(2+) or Sr(2+) concentration-dependently activated the CaR in HEK-CaR but not in non-transfected cells, but the potency of Sr(2+) varied depending on the biological response tested.	lime	10-15	CXADR pseudogene 1	Homo sapiens	77-84
17531955-3	2007	Elevating Ca(o)(2+) or Sr(2+) concentration-dependently activated the CaR in HEK-CaR but not in non-transfected cells, but the potency of Sr(2+) varied depending on the biological response tested.	strontium cation	23-29	CXADR pseudogene 1	Homo sapiens	70-73
17531955-3	2007	Elevating Ca(o)(2+) or Sr(2+) concentration-dependently activated the CaR in HEK-CaR but not in non-transfected cells, but the potency of Sr(2+) varied depending on the biological response tested.	strontium cation	23-29	CXADR pseudogene 1	Homo sapiens	77-84
17531955-5	2007	With physiological concentrations of Ca(o)(2+), Sr(2+)-induced further CaR activation.	lime	37-42	CXADR pseudogene 1	Homo sapiens	71-74
17531955-5	2007	With physiological concentrations of Ca(o)(2+), Sr(2+)-induced further CaR activation.	strontium cation	48-54	CXADR pseudogene 1	Homo sapiens	71-74
17531955-9	2007	Finally, Sr(2+) significantly increased the mRNA levels of the immediate early genes, c-fos and egr-1, which are involved in POB proliferation, and this effect was attenuated by overexpressing the dominant negative CaR.	strontium cation	9-15	CXADR pseudogene 1	Homo sapiens	215-218
17531955-10	2007	In conclusion, Sr(2+) is a full CaR agonist in HEK-CaR and POB, and, therefore, the anabolic effect of Sr(2+) on bone in vivo could be mediated, in part, by the CaR.	strontium cation	15-21	CXADR pseudogene 1	Homo sapiens	32-35
17531955-10	2007	In conclusion, Sr(2+) is a full CaR agonist in HEK-CaR and POB, and, therefore, the anabolic effect of Sr(2+) on bone in vivo could be mediated, in part, by the CaR.	strontium cation	15-21	CXADR pseudogene 1	Homo sapiens	47-54
17531955-10	2007	In conclusion, Sr(2+) is a full CaR agonist in HEK-CaR and POB, and, therefore, the anabolic effect of Sr(2+) on bone in vivo could be mediated, in part, by the CaR.	strontium cation	15-21	CXADR pseudogene 1	Homo sapiens	51-54
17376781-4	2007	Raising extracellular Ca(2+) concentration from 0.5 to 2.5 mM increased CaR(T888) phosphorylation, an effect that was potentiated stereoselectively by the calcimimetic NPS R-467.	t888	76-80	CXADR pseudogene 1	Homo sapiens	72-75
17376781-8	2007	Finally, dephosphorylation of CaR(T888) was blocked by the protein phosphatase 1/2A inhibitor calyculin, a treatment that also inhibited Ca(2+)(i) oscillations.	t888	34-38	CXADR pseudogene 1	Homo sapiens	30-33
17376781-3	2007	In HEK-293 cells stably expressing CaR (CaR-HEK), but not in cells expressing the mutant receptor CaR(T888A), phorbol ester (PMA) treatment increased CaR(pT888) immunoreactivity as observed by immunoblotting and immunofluorescence.	pt888	154-159	CXADR pseudogene 1	Homo sapiens	40-47
17376781-1	2007	The agonist sensitivity of the calcium-sensing receptor (CaR) can be altered by protein kinase C (PKC), with CaR residue Thr(888) contributing significantly to this effect.	Threonine	121-124	CXADR pseudogene 1	Homo sapiens	57-60
17376781-1	2007	The agonist sensitivity of the calcium-sensing receptor (CaR) can be altered by protein kinase C (PKC), with CaR residue Thr(888) contributing significantly to this effect.	Threonine	121-124	CXADR pseudogene 1	Homo sapiens	109-112
17376781-9	2007	In addition, calyculin/PMA cotreatment increased CaR(T888) phosphorylation in bovine parathyroid cells.	t888	53-57	CXADR pseudogene 1	Homo sapiens	49-52
17376781-2	2007	To determine whether CaR(T888) is a substrate for PKC and whether receptor activation modulates such phosphorylation, a phospho-specific antibody against this residue was raised (CaR(pT888)).	pt888	183-188	CXADR pseudogene 1	Homo sapiens	179-182
17376781-10	2007	Therefore, CaR(T888) is a substrate for receptor-induced, PKC-mediated feedback phosphorylation and can be dephosphorylated by a calyculin-sensitive phosphatase.	t888	15-19	CXADR pseudogene 1	Homo sapiens	11-14
17376781-3	2007	In HEK-293 cells stably expressing CaR (CaR-HEK), but not in cells expressing the mutant receptor CaR(T888A), phorbol ester (PMA) treatment increased CaR(pT888) immunoreactivity as observed by immunoblotting and immunofluorescence.	Tetradecanoylphorbol Acetate	125-128	CXADR pseudogene 1	Homo sapiens	35-38
17376781-3	2007	In HEK-293 cells stably expressing CaR (CaR-HEK), but not in cells expressing the mutant receptor CaR(T888A), phorbol ester (PMA) treatment increased CaR(pT888) immunoreactivity as observed by immunoblotting and immunofluorescence.	Tetradecanoylphorbol Acetate	125-128	CXADR pseudogene 1	Homo sapiens	40-43
17291602-4	2007	The genes encoding for organic anion uptake (NTCP, OATPs), canalicular export (BSEP, MRP2) and alternative basolateral export (MRP3, MRP4) in liver are regulated by a complex interacting network of hepatocyte nuclear factors (HNF1, 3, 4) and nuclear (orphan) receptors (e.g., FXR, PXR, CAR, RAR, LRH-1, SHP, GR).	periodate-oxidized adenosine 5'-triphosphate	51-56	CXADR pseudogene 1	Homo sapiens	286-289
17376781-3	2007	In HEK-293 cells stably expressing CaR (CaR-HEK), but not in cells expressing the mutant receptor CaR(T888A), phorbol ester (PMA) treatment increased CaR(pT888) immunoreactivity as observed by immunoblotting and immunofluorescence.	Tetradecanoylphorbol Acetate	125-128	CXADR pseudogene 1	Homo sapiens	40-43
17313273-6	2007	Oxygen cost decreased significantly by 6% (p &lt; or = 0.05) only for CAR, whereas the respiratory exchange ratio decreased significantly (p &lt; or = 0.05) for both WLK (0.84-0.81) and STR (0.87-0.83), and heart rate decreased significantly (p &lt; or = 0.05) only for CAR.	Oxygen	0-6	CXADR pseudogene 1	Homo sapiens	70-73
16472767-8	2006	HAEC express a functional CaR that responds to the endogenous polyamine spermine with an increase in [Ca(2+)](i), primarily due to release of IP(3)- and ryanodine-sensitive intracellular Ca(2+) stores, leading to the production of NO.	polyamine spermine	62-80	CXADR pseudogene 1	Homo sapiens	26-29
16407414-4	2006	Cotreatment with the Rho kinase inhibitors Y-27632 and H1152 attenuated the CaR-induced morphological change but not intracellular Ca2+ (Ca2+(i)) mobilization or ERK activation, although transfection with a dominant-negative RhoA-binding protein also inhibited calcimimetic-induced actin stress fiber assembly.	Y 27632	43-50	CXADR pseudogene 1	Homo sapiens	76-79
16407414-4	2006	Cotreatment with the Rho kinase inhibitors Y-27632 and H1152 attenuated the CaR-induced morphological change but not intracellular Ca2+ (Ca2+(i)) mobilization or ERK activation, although transfection with a dominant-negative RhoA-binding protein also inhibited calcimimetic-induced actin stress fiber assembly.	2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine	55-60	CXADR pseudogene 1	Homo sapiens	76-79
16407414-8	2006	In addition, this study provides further evidence that aromatic amino acids elicit differential signaling from other CaR agonists.	Amino Acids, Aromatic	55-75	CXADR pseudogene 1	Homo sapiens	117-120
16472767-8	2006	HAEC express a functional CaR that responds to the endogenous polyamine spermine with an increase in [Ca(2+)](i), primarily due to release of IP(3)- and ryanodine-sensitive intracellular Ca(2+) stores, leading to the production of NO.	Inositol 1,4,5-Trisphosphate	142-147	CXADR pseudogene 1	Homo sapiens	26-29
16472767-8	2006	HAEC express a functional CaR that responds to the endogenous polyamine spermine with an increase in [Ca(2+)](i), primarily due to release of IP(3)- and ryanodine-sensitive intracellular Ca(2+) stores, leading to the production of NO.	Ryanodine	153-162	CXADR pseudogene 1	Homo sapiens	26-29
15146554-4	2004	Moderately increased expression of CAR was determined in cisplatin-resistant CA3ST cells using flow cytometry and measurement of wild-type adenovirus Ad5CMVbetagal attachment.	Cisplatin	57-66	CXADR pseudogene 1	Homo sapiens	35-38
16684649-0	2006	Phenobarbital confers its diverse effects by activating the orphan nuclear receptor car.	Phenobarbital	0-13	CXADR pseudogene 1	Homo sapiens	84-87
16684649-3	2006	Upon activation by PB and numerous PB-type inducers, the nuclear receptor CAR mediates those pleiotropic actions by regulating various hepatic genes, utilizing multiple regulatory mechanisms.	Phenobarbital	19-21	CXADR pseudogene 1	Homo sapiens	74-77
15582450-7	2005	Under these conditions, the addition of beta-carotene (Car) suppresses the O(2)((1)Delta(g))-mediated photooxidation.	o(2)	75-79	CXADR pseudogene 1	Homo sapiens	40-59
16152947-0	2005	Analysis of the chloroacetanilide herbicides in water using SPME with CAR/PDMS and GC/ECD.	2-chloroacetanilide	16-33	CXADR pseudogene 1	Homo sapiens	70-73
16152947-0	2005	Analysis of the chloroacetanilide herbicides in water using SPME with CAR/PDMS and GC/ECD.	Water	48-53	CXADR pseudogene 1	Homo sapiens	70-73
17281509-3	2005	Within a few minutes, a cable car facilitates an ascent from 1702 m to 2700 m above sea level, where the partial pressure of oxygen is about 550 mmHg (as compared to 760 mmHg at sea level).	Oxygen	125-131	CXADR pseudogene 1	Homo sapiens	30-33
15146554-9	2004	The implication of CAR in increased adenoviral transduction efficacy in cisplatin resistant CA3ST cells was further assessed by transduction experiments using adenoviral mutant Ad5FbDelta639 whose entry is only to a very small extent dependent on the presence of CAR.	Cisplatin	72-81	CXADR pseudogene 1	Homo sapiens	19-22
15146554-11	2004	Thus, the data presented provide evidence that both alphavbeta3 integrin and CAR are involved in increased adenoviral transduction efficacy in cisplatin resistant CA3ST cells.	Cisplatin	143-152	CXADR pseudogene 1	Homo sapiens	77-80
15067332-3	2004	The extracellular calcium ion concentration sensing receptor CaR is a 123 kDa G-protein coupled membrane protein that resides within caveolin-rich regions as a dimer.	Calcium	18-25	CXADR pseudogene 1	Homo sapiens	61-64
14988430-3	2004	Considered a xenobiotic sensing receptor, CAR transcriptionally modifies the expression of genes involved in the metabolism and elimination of xenobiotics and steroids in response to these compounds and other cellular metabolites.	Steroids	159-167	CXADR pseudogene 1	Homo sapiens	42-45
15004017-4	2004	We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1.	sulfate hydroxy-bile acids	134-160	CXADR pseudogene 1	Homo sapiens	40-43
15004017-4	2004	We determined that the nuclear receptor CAR is required to coordinately up-regulate hepatic expression of Mrp4 and an enzyme known to sulfate hydroxy-bile acids and steroids, Sult2a1.	Steroids	165-173	CXADR pseudogene 1	Homo sapiens	40-43
15067332-6	2004	The role of CaR in sensing and responding to extracellular calcium ion concentration, [Ca2+]o, and neomycin sulfate, and spatial interactions of CaR with calbindin-D28k in MCF-7 human breast cancer cells were studied.	Calcium	59-66	CXADR pseudogene 1	Homo sapiens	12-15
15067332-9	2004	The normalized dose response curves fitting yielded Hill co-efficient values of 4.32+/-0.63 and 1.49+/-0.14 for Ca2+ and neomycin sulfate respectively, thus indicating highly co-operative, 4-5 binding sites for Ca2+ and 1-2 binding site(s) for neomycin sulfate on CaR.	Neomycin	121-137	CXADR pseudogene 1	Homo sapiens	264-267
15067332-11	2004	The confocal microscopy data, obtained by using a highly sensitive tyramide signal amplification technology for immunofluorescence detection, showed CaR and calbindin-D28k were co-localized when cells were exposed to 200 micro M neomycin sulfate, whereas in control cells there was no co-localization of these two proteins.	tyramide	67-75	CXADR pseudogene 1	Homo sapiens	149-152
15067332-11	2004	The confocal microscopy data, obtained by using a highly sensitive tyramide signal amplification technology for immunofluorescence detection, showed CaR and calbindin-D28k were co-localized when cells were exposed to 200 micro M neomycin sulfate, whereas in control cells there was no co-localization of these two proteins.	Neomycin	229-245	CXADR pseudogene 1	Homo sapiens	149-152
12904257-0	2003	Complex effects of rexinoids on ligand dependent activation or inhibition of the xenobiotic receptor, CAR.	rexinoids	19-28	CXADR pseudogene 1	Homo sapiens	102-105
14677060-1	2004	UNLABELLED: Gain-of-function mutations of the extracellular calcium (Ca(2+)e)-sensing receptor (CaR) have been identified in patients with familial and sporadic hypercalciuric hypocalcaemia.	Calcium	60-67	CXADR pseudogene 1	Homo sapiens	96-99
12904257-4	2003	RESULTS: Direct protein-protein interaction studies demonstrate that the RXR agonist 9-cis-RA increases interaction of CAR/RXR heterodimers with the coactivator SRC-3, but also inhibits the ability of TCPOBOP to increase and androstanol to decrease coactivator binding.	Tretinoin	85-93	CXADR pseudogene 1	Homo sapiens	119-122
12551994-4	2003	We found that CAR is localized to a novel lipid-rich microdomain similar to that of the low-density lipoprotein receptor (LDLR) but distinct from that of a CAR variant that exhibited traditional lipid raft localization via fusion to a glycosylphosphatidylinositol (GPI) tail.	Glycosylphosphatidylinositols	235-263	CXADR pseudogene 1	Homo sapiens	14-17
12551994-4	2003	We found that CAR is localized to a novel lipid-rich microdomain similar to that of the low-density lipoprotein receptor (LDLR) but distinct from that of a CAR variant that exhibited traditional lipid raft localization via fusion to a glycosylphosphatidylinositol (GPI) tail.	Glycosylphosphatidylinositols	265-268	CXADR pseudogene 1	Homo sapiens	14-17
11033069-2	2000	This minireview deals with the mechanisms by which phenobarbital and phenobarbital-type chemicals induce cytochrome P450 and other genes, and summarises the knowledge on the role of the constitutively active receptor CAR in the induction process.	Phenobarbital	51-64	CXADR pseudogene 1	Homo sapiens	217-220
11701443-2	2001	Elevated extracellular calcium concentrations ([Ca(2+)](o)) stimulate parathyroid hormone-related protein (PTHrP) secretion from normal and malignant cells, potentially acting via the [Ca(2+)](o)-sensing receptor (CaR).	Calcium	23-30	CXADR pseudogene 1	Homo sapiens	214-217
11701443-6	2001	The polycationic CaR agonists [Ca(2+)](o), neomycin, and spermine each concentration dependently stimulated PTHrP secretion from PC-3 cells, as measured by immunoradiometric assay, with maximal, 3.2-, 3.6-, and 4.2-fold increases, respectively.	Neomycin	43-51	CXADR pseudogene 1	Homo sapiens	17-20
11701443-6	2001	The polycationic CaR agonists [Ca(2+)](o), neomycin, and spermine each concentration dependently stimulated PTHrP secretion from PC-3 cells, as measured by immunoradiometric assay, with maximal, 3.2-, 3.6-, and 4.2-fold increases, respectively.	Spermine	57-65	CXADR pseudogene 1	Homo sapiens	17-20
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Calcium	68-75	CXADR pseudogene 1	Homo sapiens	108-111
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Calcium	68-75	CXADR pseudogene 1	Homo sapiens	230-233
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Disulfides	119-128	CXADR pseudogene 1	Homo sapiens	108-111
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Disulfides	119-128	CXADR pseudogene 1	Homo sapiens	230-233
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Cysteine	151-159	CXADR pseudogene 1	Homo sapiens	108-111
11069904-1	2001	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca(2+)](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications.	Cysteine	151-159	CXADR pseudogene 1	Homo sapiens	230-233
11069904-2	2001	In this study, we have investigated which of these disulfide linkages are essential for dimerization of the CaR and whether they are required for these functional interactions.	Disulfides	51-60	CXADR pseudogene 1	Homo sapiens	108-111
11069904-3	2001	Our results confirm the key roles of Cys(129) and Cys(131) in CaR dimerization.	Cysteine	37-40	CXADR pseudogene 1	Homo sapiens	62-65
11069904-3	2001	Our results confirm the key roles of Cys(129) and Cys(131) in CaR dimerization.	Cysteine	50-53	CXADR pseudogene 1	Homo sapiens	62-65
11069904-5	2001	In addition, reconstitution of CaR-mediated signaling by cotransfection of two individually inactive mutant CaRs is nearly identical in the presence or absence of both Cys(129) and Cys(131), showing that covalent linkage of CaR dimers is not needed for functional interactions between CaR monomers.	Cysteine	168-171	CXADR pseudogene 1	Homo sapiens	31-34
11069904-5	2001	In addition, reconstitution of CaR-mediated signaling by cotransfection of two individually inactive mutant CaRs is nearly identical in the presence or absence of both Cys(129) and Cys(131), showing that covalent linkage of CaR dimers is not needed for functional interactions between CaR monomers.	Cysteine	181-184	CXADR pseudogene 1	Homo sapiens	31-34
11069904-6	2001	These findings suggest that the CaR has at least two distinct types of motifs mediating dimerization and functional interactions, i.e. covalent interactions involving intermolecular disulfide bonds and noncovalent, possibly hydrophobic, interactions.	Disulfides	182-191	CXADR pseudogene 1	Homo sapiens	32-35
11097627-1	2000	The extracellular Ca(2+)-sensing receptor (CaR) responds to polycations, including Ca(2+) and neomycin.	Neomycin	94-102	CXADR pseudogene 1	Homo sapiens	43-46
11097627-3	2000	A number of divalent cations, including Pb(2+), Co(2+), Cd(2+), and Fe(2+), are toxic to the kidney, brain, and other tissues where the CaR is expressed.	Lead	40-46	CXADR pseudogene 1	Homo sapiens	136-139
11097627-3	2000	A number of divalent cations, including Pb(2+), Co(2+), Cd(2+), and Fe(2+), are toxic to the kidney, brain, and other tissues where the CaR is expressed.	Cobalt(2+)	48-54	CXADR pseudogene 1	Homo sapiens	136-139
11097627-3	2000	A number of divalent cations, including Pb(2+), Co(2+), Cd(2+), and Fe(2+), are toxic to the kidney, brain, and other tissues where the CaR is expressed.	ammonium ferrous sulfate	68-74	CXADR pseudogene 1	Homo sapiens	136-139
11097627-6	2000	Extracellular Ca(2+), Ba(2+), Cd(2+), Co(2+), Fe(2+), Gd(3+), Ni(2+), Pb(2+), and neomycin activated the CaR, but Hg(2+) and Fe(3+) did not.	Cobalt(2+)	38-44	CXADR pseudogene 1	Homo sapiens	105-108
11097627-6	2000	Extracellular Ca(2+), Ba(2+), Cd(2+), Co(2+), Fe(2+), Gd(3+), Ni(2+), Pb(2+), and neomycin activated the CaR, but Hg(2+) and Fe(3+) did not.	Iron	125-127	CXADR pseudogene 1	Homo sapiens	105-108
11097627-7	2000	We analyzed the kinetics of activation of p42ERK and PLA(2) by the CaR in response to Ca(2+), Co(2+), and Pb(2+).	Cobalt(2+)	94-100	CXADR pseudogene 1	Homo sapiens	67-70
11706745-1	2000	The cloning of the CaR has made it possible to show definitively that the CaR is a critical mediator of the inhibitory effect of high Cao2+ on PTH secretion and parathyroid cellular proliferation.	cao2+	134-139	CXADR pseudogene 1	Homo sapiens	19-22
11706745-1	2000	The cloning of the CaR has made it possible to show definitively that the CaR is a critical mediator of the inhibitory effect of high Cao2+ on PTH secretion and parathyroid cellular proliferation.	cao2+	134-139	CXADR pseudogene 1	Homo sapiens	74-77
11850127-6	2002	Here, we have found that Ca(2+)-stimulated STC secretion in salmon is mimicked by CaR mimetics, pharmacological agents that increase the sensitivity of the CaR to calcium.	Calcium	163-170	CXADR pseudogene 1	Homo sapiens	82-85
11850127-6	2002	Here, we have found that Ca(2+)-stimulated STC secretion in salmon is mimicked by CaR mimetics, pharmacological agents that increase the sensitivity of the CaR to calcium.	Calcium	163-170	CXADR pseudogene 1	Homo sapiens	156-159
11097627-7	2000	We analyzed the kinetics of activation of p42ERK and PLA(2) by the CaR in response to Ca(2+), Co(2+), and Pb(2+).	Lead	106-108	CXADR pseudogene 1	Homo sapiens	67-70
11097627-10	2000	Submaximal concentrations of Ca(2+) and Pb(2+) were additive for activation of the CaR.	Lead	40-46	CXADR pseudogene 1	Homo sapiens	83-86
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	Lead	202-204	CXADR pseudogene 1	Homo sapiens	19-22
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	Lead	202-204	CXADR pseudogene 1	Homo sapiens	138-141
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	Cobalt(2+)	218-224	CXADR pseudogene 1	Homo sapiens	19-22
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	Cobalt(2+)	218-224	CXADR pseudogene 1	Homo sapiens	138-141
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	ammonium ferrous sulfate	230-236	CXADR pseudogene 1	Homo sapiens	19-22
11097627-14	2000	The facts that the CaR is a promiscuous polycation sensor and that the effects of these ions are additive to activate it suggest that the CaR may contribute to the toxicity of some heavy metals such as Pb(2+), Cd(2+), Co(2+), and Fe(2+) for the kidney and other tissues where it is expressed.	ammonium ferrous sulfate	230-236	CXADR pseudogene 1	Homo sapiens	138-141
11027630-0	2000	Phenobarbital-elicited activation of nuclear receptor CAR in induction of cytochrome P450 genes.	Phenobarbital	0-13	CXADR pseudogene 1	Homo sapiens	54-57
11027630-3	2000	In response to PB exposure, CAR in the cytoplasm translocates into the nucleus, forms a heterodimer with the retinoid X receptor, and activates the PB response enhancer element leading to the concerted induction of numerous genes.	Phenobarbital	15-17	CXADR pseudogene 1	Homo sapiens	28-31
11027630-3	2000	In response to PB exposure, CAR in the cytoplasm translocates into the nucleus, forms a heterodimer with the retinoid X receptor, and activates the PB response enhancer element leading to the concerted induction of numerous genes.	Phenobarbital	148-150	CXADR pseudogene 1	Homo sapiens	28-31
11033069-2	2000	This minireview deals with the mechanisms by which phenobarbital and phenobarbital-type chemicals induce cytochrome P450 and other genes, and summarises the knowledge on the role of the constitutively active receptor CAR in the induction process.	Phenobarbital	69-82	CXADR pseudogene 1	Homo sapiens	217-220
11996099-7	2000	It is also possible that the pleiotropic effects of PB can, in part, be explained by the ability of the CAR-RXR heterodimer to bind to a variety of nuclear receptor binding motifs.	Phenobarbital	52-54	CXADR pseudogene 1	Homo sapiens	104-107
11033758-2	2000	Cloning of the CaR has enabled identification of FHH and NSHPT as inherited conditions with generalized resistance to Ca2+o, which is caused in many cases by inactivating mutations in the CaR gene.	ca2+o	118-123	CXADR pseudogene 1	Homo sapiens	15-18
11033758-2	2000	Cloning of the CaR has enabled identification of FHH and NSHPT as inherited conditions with generalized resistance to Ca2+o, which is caused in many cases by inactivating mutations in the CaR gene.	ca2+o	118-123	CXADR pseudogene 1	Homo sapiens	188-191
11033758-10	2000	As discussed elsewhere in this issue, selective calcimimetic CaR activators are being tested in clinical trials, which potentiate the activation of the CaR by Ca2+o, thereby resetting the elevated set point for Ca2+o-regulated PTH release in primary and secondary hyperparathyroidism toward normal.	ca2+o	159-164	CXADR pseudogene 1	Homo sapiens	61-64
11033758-10	2000	As discussed elsewhere in this issue, selective calcimimetic CaR activators are being tested in clinical trials, which potentiate the activation of the CaR by Ca2+o, thereby resetting the elevated set point for Ca2+o-regulated PTH release in primary and secondary hyperparathyroidism toward normal.	ca2+o	159-164	CXADR pseudogene 1	Homo sapiens	152-155
11033758-10	2000	As discussed elsewhere in this issue, selective calcimimetic CaR activators are being tested in clinical trials, which potentiate the activation of the CaR by Ca2+o, thereby resetting the elevated set point for Ca2+o-regulated PTH release in primary and secondary hyperparathyroidism toward normal.	ca2+o	211-216	CXADR pseudogene 1	Homo sapiens	61-64
11033758-10	2000	As discussed elsewhere in this issue, selective calcimimetic CaR activators are being tested in clinical trials, which potentiate the activation of the CaR by Ca2+o, thereby resetting the elevated set point for Ca2+o-regulated PTH release in primary and secondary hyperparathyroidism toward normal.	ca2+o	211-216	CXADR pseudogene 1	Homo sapiens	152-155
10781086-1	2000	The extracellular calcium (Ca(2+)(o))-sensing receptor (CaR) recognizes and responds to (i.e., "senses") Ca(2+)(o) as its principal physiological ligand.	Calcium	18-25	CXADR pseudogene 1	Homo sapiens	56-59
10781086-2	2000	In the present studies, we document that the CaR is activated not only by extracellular calcium ions but also by amino acids, establishing its capacity to sense nutrients of two totally different classes.	Calcium	88-95	CXADR pseudogene 1	Homo sapiens	45-48
10781086-7	2000	l-amino acid mixtures emulating the amino acid composition of fasting human plasma reproduced the effects of high concentrations of individual l-amino acids on Ca(2+) mobilization and enhanced the sensitivity of the CaR to Ca(2+)(o).	Amino Acids	0-12	CXADR pseudogene 1	Homo sapiens	216-219
10781086-8	2000	The data presented herein identify the CaR as a molecular target for aromatic and other l-amino acids.	Amino Acids	88-101	CXADR pseudogene 1	Homo sapiens	39-42
10781086-10	2000	The actions of l-amino acids on the CaR may provide explanations for several long recognized but poorly understood actions of dietary protein on calcium metabolism.	Amino Acids	15-28	CXADR pseudogene 1	Homo sapiens	36-39
10781086-10	2000	The actions of l-amino acids on the CaR may provide explanations for several long recognized but poorly understood actions of dietary protein on calcium metabolism.	Calcium	145-152	CXADR pseudogene 1	Homo sapiens	36-39
10757780-0	2000	The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR.	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	24-66	CXADR pseudogene 1	Homo sapiens	113-116
10757780-3	2000	CAR has previously been shown to be an apparently constitutive transactivator, and this constitutive activity is inhibited by androstanes acting as inverse agonists.	Androstanes	126-137	CXADR pseudogene 1	Homo sapiens	0-3
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	61-104	CXADR pseudogene 1	Homo sapiens	9-12
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	106-113	CXADR pseudogene 1	Homo sapiens	9-12
10757780-5	2000	However, CAR transactivation is increased in the presence of 1,4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP), the most potent known member of the phenobarbital-like class of CYP-inducing agents.	Phenobarbital	152-165	CXADR pseudogene 1	Homo sapiens	9-12
10809383-3	2000	This mechanism, which is voltage independent and most sensitive around physiologic calcium concentrations, is regulated through a 120 kDa calcium sensing receptor, CaR.	Calcium	83-90	CXADR pseudogene 1	Homo sapiens	164-167
11322513-1	2000	The cloning of a G protein-coupled, extracellular Ca2+ (Ca2+(o))-sensing receptor (CaR) has afforded a molecular basis for a number of the known effects of Ca2+(o) on tissues involved in maintaining systemic calcium homeostasis, especially parathyroid gland and kidney.	Calcium	208-215	CXADR pseudogene 1	Homo sapiens	83-86
10907347-0	2000	[Calcium receptor (CaR): a new approach to regulation of calcium homeostasis].	Calcium	57-64	CXADR pseudogene 1	Homo sapiens	19-22
10907347-1	2000	In recent years the receptor sensing calcium (CaR) has been discovered on the surface of parathyroid cells and some other organs cells which revised our understanding of mechanisms involved in regulation of body calcium balance.	Calcium	37-44	CXADR pseudogene 1	Homo sapiens	46-49
10907347-1	2000	In recent years the receptor sensing calcium (CaR) has been discovered on the surface of parathyroid cells and some other organs cells which revised our understanding of mechanisms involved in regulation of body calcium balance.	Calcium	212-219	CXADR pseudogene 1	Homo sapiens	46-49
10907347-2	2000	It was shown that stimulation of CaR induced by an increase of extracellular ionized calcium concentration resulted in an increase of intracellular calcium and subsequent decrease of parathyroid hormone (PTH) secretion from parathyroid cells.	Calcium	85-92	CXADR pseudogene 1	Homo sapiens	33-36
10907347-2	2000	It was shown that stimulation of CaR induced by an increase of extracellular ionized calcium concentration resulted in an increase of intracellular calcium and subsequent decrease of parathyroid hormone (PTH) secretion from parathyroid cells.	Calcium	148-155	CXADR pseudogene 1	Homo sapiens	33-36
10907347-4	2000	Investigations on CaR structure revealed the mutations in those inherited syndromes leading to increase or decrease of parathyroid and nephron cells receptor sensitivity to calcium.	Calcium	173-180	CXADR pseudogene 1	Homo sapiens	18-21
10907347-5	2000	The description of the receptor properties resulted in development of a new group of compounds called calcimimetics which are more efficient than calcium itself in stimulation of CaR and subsequent decrease of PTH secretion.	Calcium	146-153	CXADR pseudogene 1	Homo sapiens	179-182
9742082-0	1998	The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene.	Phenobarbital	78-91	CXADR pseudogene 1	Homo sapiens	28-31
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Phenobarbital	235-248	CXADR pseudogene 1	Homo sapiens	74-77
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Phenobarbital	235-248	CXADR pseudogene 1	Homo sapiens	250-253
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Pregnenolone Carbonitrile	256-289	CXADR pseudogene 1	Homo sapiens	74-77
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Pregnenolone Carbonitrile	256-289	CXADR pseudogene 1	Homo sapiens	250-253
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	CXADR pseudogene 1	Homo sapiens	74-77
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Rifampin	294-304	CXADR pseudogene 1	Homo sapiens	250-253
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Clofibric Acid	316-330	CXADR pseudogene 1	Homo sapiens	74-77
10462436-3	1999	Roles for three "orphan" nuclear receptor superfamily members, designated CAR, PXR, and PPAR, in respectively mediating the induction of hepatic P450s belonging to families CYP2, CYP3, and CYP4 in response to the prototypical inducers phenobarbital (CAR), pregnenolone 16alpha-carbonitrile and rifampicin (PXR), and clofibric acid (PPAR) have now been established.	Clofibric Acid	316-330	CXADR pseudogene 1	Homo sapiens	250-253
10037683-0	1999	The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene.	Phenobarbital	47-60	CXADR pseudogene 1	Homo sapiens	31-34
10037683-1	1999	The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG2 cells either transiently or stably transfected with a nuclear receptor CAR expression vector.	Phenobarbital	35-48	CXADR pseudogene 1	Homo sapiens	164-167
10037683-1	1999	The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG2 cells either transiently or stably transfected with a nuclear receptor CAR expression vector.	Phenobarbital	50-52	CXADR pseudogene 1	Homo sapiens	164-167
10037683-1	1999	The endogenous CYP2B6 gene becomes phenobarbital (PB) inducible in androstenol-treated HepG2 cells either transiently or stably transfected with a nuclear receptor CAR expression vector.	Androstenols	67-78	CXADR pseudogene 1	Homo sapiens	164-167
10037683-5	1999	In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells.	Steroids	50-57	CXADR pseudogene 1	Homo sapiens	22-25
10037683-5	1999	In addition to PBREM, CAR also transactivates the steroid/rifampicin-response element of the human CYP3A4 gene in HepG2 cells.	Rifampin	58-68	CXADR pseudogene 1	Homo sapiens	22-25
10037683-6	1999	Thus, activation of the repressed nuclear receptor CAR appears to be a versatile mediator that regulates PB induction of the CYP2B and other genes.	Phenobarbital	105-107	CXADR pseudogene 1	Homo sapiens	51-54
10098531-10	1999	CaR antisense oligonucleotides suppressed the expression of CaR protein and enhanced RNA levels of aggrecan in C5.18 cells.	Oligonucleotides	14-30	CXADR pseudogene 1	Homo sapiens	0-3
10098531-10	1999	CaR antisense oligonucleotides suppressed the expression of CaR protein and enhanced RNA levels of aggrecan in C5.18 cells.	Oligonucleotides	14-30	CXADR pseudogene 1	Homo sapiens	60-63
9801147-2	1998	To investigate the role of these cysteines, a series of mutants in the extracellular domain of the human CaR was prepared in which each of these 16 cysteine residues and three others not conserved in the mGluRs were replaced by serines.	Cysteine	33-42	CXADR pseudogene 1	Homo sapiens	105-108
9801147-2	1998	To investigate the role of these cysteines, a series of mutants in the extracellular domain of the human CaR was prepared in which each of these 16 cysteine residues and three others not conserved in the mGluRs were replaced by serines.	Cysteine	33-41	CXADR pseudogene 1	Homo sapiens	105-108
9801147-2	1998	To investigate the role of these cysteines, a series of mutants in the extracellular domain of the human CaR was prepared in which each of these 16 cysteine residues and three others not conserved in the mGluRs were replaced by serines.	Serine	228-235	CXADR pseudogene 1	Homo sapiens	105-108
9801147-3	1998	Wild-type and mutant CaR cDNAs were expressed in HEK-293 cells, and evaluated for expression and response to extracellular calcium.	Calcium	123-130	CXADR pseudogene 1	Homo sapiens	21-24
9742082-6	1998	PBREM was synergistically activated by transfection of CAR and RXR in HepG2 and HEK293 cells when the NR1 site was functional.	pbrem	0-5	CXADR pseudogene 1	Homo sapiens	55-58
9742082-7	1998	A CAR-RXR heterodimer has thus been characterized as a trans-acting factor for the phenobarbital-inducible Cyp2b10 gene.	Phenobarbital	83-96	CXADR pseudogene 1	Homo sapiens	2-5
9467597-1	1998	The extracellular calcium (Ca2+o)-sensing receptor (CaR) plays a critical role in maintaining Ca2+o homeostasis in mammals by virtue of its presence in parathyroid gland and kidney.	Calcium	18-25	CXADR pseudogene 1	Homo sapiens	52-55
9661634-5	1998	A heterozygous missense mutation substituting a cysteine for the phenylalanine normally present at codon 788 (F788C) was identified in the CaR"s fifth transmembrane domain and was shown to cosegregate with the disease.	Cysteine	48-56	CXADR pseudogene 1	Homo sapiens	139-142
9661634-5	1998	A heterozygous missense mutation substituting a cysteine for the phenylalanine normally present at codon 788 (F788C) was identified in the CaR"s fifth transmembrane domain and was shown to cosegregate with the disease.	Phenylalanine	65-78	CXADR pseudogene 1	Homo sapiens	139-142
9661634-10	1998	Thus, we confirm that 1) a gain of function mutation in the fifth transmembrane domain of the CaR causes severe familial hypoparathyroidism by rendering the receptor more sensitive than normal to activation by Ca2+e; 2) some patients in the family do not experience seizures despite their severe hypocalcemia; and 3) this condition needs to be differentiated from other causes of hypoparathyroidism.	ca2+e	210-215	CXADR pseudogene 1	Homo sapiens	94-97
9486404-7	1998	Since we have shown previously that cC1qR/CaR is able to inhibit the haemolytic activity of Clq, we determined a possible pathogenic role for anti-cC1qR/CaR on complement regulation.	(R)-chloroquine	92-95	CXADR pseudogene 1	Homo sapiens	42-45
9486404-7	1998	Since we have shown previously that cC1qR/CaR is able to inhibit the haemolytic activity of Clq, we determined a possible pathogenic role for anti-cC1qR/CaR on complement regulation.	(R)-chloroquine	92-95	CXADR pseudogene 1	Homo sapiens	153-156
9467597-1	1998	The extracellular calcium (Ca2+o)-sensing receptor (CaR) plays a critical role in maintaining Ca2+o homeostasis in mammals by virtue of its presence in parathyroid gland and kidney.	ca2+o	27-32	CXADR pseudogene 1	Homo sapiens	52-55
9467597-1	1998	The extracellular calcium (Ca2+o)-sensing receptor (CaR) plays a critical role in maintaining Ca2+o homeostasis in mammals by virtue of its presence in parathyroid gland and kidney.	ca2+o	94-99	CXADR pseudogene 1	Homo sapiens	52-55
8854047-3	1996	Several of the tissues expressing the CaR are important elements in the calcium homeostatic system that have long been known to be capable of sensing [Ca2+]o, such as parathyroid and thyroidal C cells.	Calcium	72-79	CXADR pseudogene 1	Homo sapiens	38-41
9321880-4	1997	Moreover, amino acid residues where mutations cause disorders of Cao(2+)-sensing in the human CaR share the wild-type human sequence in the chicken CaR.	cao(2+)	65-72	CXADR pseudogene 1	Homo sapiens	94-97
9141253-1	1997	Carnitine CAR) plays an important role in the beta-oxidation of fatty acids.	Carnitine	0-9	CXADR pseudogene 1	Homo sapiens	10-13
9141253-1	1997	Carnitine CAR) plays an important role in the beta-oxidation of fatty acids.	Fatty Acids	64-75	CXADR pseudogene 1	Homo sapiens	10-13
8783675-2	1996	The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from the parathyroid gland and the kidney has provided novel insights into the mechanisms that underlie the direct actions of Ca2+o on various cells.	Calcium	39-46	CXADR pseudogene 1	Homo sapiens	73-76
8783675-2	1996	The recent cloning of an extracellular calcium (Ca2+o)-sensing receptor (CaR) from the parathyroid gland and the kidney has provided novel insights into the mechanisms that underlie the direct actions of Ca2+o on various cells.	ca2+o	48-53	CXADR pseudogene 1	Homo sapiens	73-76
8783675-6	1996	In the kidney, the CaR directly inhibits tubular reabsorption of calcium and magnesium in the thick ascending limb, and may be responsible for the long-recognized, but poorly understood inhibition of urinary concentrating ability by hypercalcemia.	Calcium	65-72	CXADR pseudogene 1	Homo sapiens	19-22
8783675-6	1996	In the kidney, the CaR directly inhibits tubular reabsorption of calcium and magnesium in the thick ascending limb, and may be responsible for the long-recognized, but poorly understood inhibition of urinary concentrating ability by hypercalcemia.	Magnesium	77-86	CXADR pseudogene 1	Homo sapiens	19-22
9101368-1	1997	The extracellular Ca2+ (Ca(0)2+)-sensing receptor (CaR) recently cloned from mammalian parathyroid, kidney, brain, and thyroid plays a central role in maintaining near constancy of Ca(0)2+.	ca(0)2+	24-31	CXADR pseudogene 1	Homo sapiens	51-54
8853437-2	1996	Inactivating mutations of the CaR in the inherited human disorder, familial hypocalciuric hypercalcemia, cause reduced responsiveness of the parathyroid to extracellular Ca2+ (Cao2+), as well as abnormally avid renal tubular reabsorption of both Ca2+ and Mg2+ in the distal tubule, suggesting an important role for the CaR in regulating parathyroid hormone (PTH) secretion and renal handling of divalent cations.	cao2+	176-181	CXADR pseudogene 1	Homo sapiens	30-33
8853437-2	1996	Inactivating mutations of the CaR in the inherited human disorder, familial hypocalciuric hypercalcemia, cause reduced responsiveness of the parathyroid to extracellular Ca2+ (Cao2+), as well as abnormally avid renal tubular reabsorption of both Ca2+ and Mg2+ in the distal tubule, suggesting an important role for the CaR in regulating parathyroid hormone (PTH) secretion and renal handling of divalent cations.	magnesium ion	255-259	CXADR pseudogene 1	Homo sapiens	30-33
8854047-11	1996	Finally, it would not be surprising to discover additional receptors for [Ca2+]o or for other ions (the CaR may, in fact, be an important [Mg2+]o-sensor) that could function abnormally in certain disease states and be amenable to pharmacological manipulation with ion receptor-based therapeutics.	magnesium ion	139-143	CXADR pseudogene 1	Homo sapiens	104-107
33776569-2	2021	The aim of this study was to evaluate the effects of Zn supplementation on serum copper (Cu) to Zn and C-reactive protein (CRP) to albumin ratios (CAR) in HD patients.	Zinc	53-55	CXADR pseudogene 1	Homo sapiens	147-150
7859820-1	1994	Recoverin is a calcium-binding protein identified as an autoantigen in a paraneoplastic degenerative disease of the human retina known as cancer-associated retinopathy (CAR).	Calcium	15-22	CXADR pseudogene 1	Homo sapiens	138-173
33776569-9	2021	In parallel, serum albumin concentrations significantly increased, and CAR decreased in Zn supplemented group only.	Zinc	88-90	CXADR pseudogene 1	Homo sapiens	71-74
34964902-9	2021	Linsitinib, but not BMS-754807, decreases activation/exhaustion of GD2-CAR T-cells and increases their central memory profile.	3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol	0-10	CXADR pseudogene 1	Homo sapiens	71-74
34974445-4	2022	L-carnitine (L-CAR) is known for its antioxidant properties, which can protect against neuronal damage.	Carnitine	0-11	CXADR pseudogene 1	Homo sapiens	15-18
34116862-8	2022	DP-CAR group had similar R0 resection compared with DP group (71.4% vs 87.3%, P = 0.090).	dp	0-2	CXADR pseudogene 1	Homo sapiens	3-6
34964902-10	2021	The enhanced anti-tumor activity of linsitinib/GD2-CAR T-cell combination was confirmed in DIPG models in vitro, ex vivo and in vivo.	3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol	36-46	CXADR pseudogene 1	Homo sapiens	51-54
34893603-4	2021	CAR19 T cells are manufactured under current good manufacturing practices (cGMP) at two disparate clinical sites, Moscow (Russia) and Cleveland (USA).	Cyclic GMP	75-79	CXADR pseudogene 1	Homo sapiens	0-5
34819055-2	2021	Sulforaphane (SFN) is known to play an important role in inhibiting tumor growth, but its effect on CAR-T cells remains unclear.	sulforaphane	0-12	CXADR pseudogene 1	Homo sapiens	100-103
34497035-9	2021	CAR was found to be an independent risk factor for diabetic nephropathy (adjusted to age, BMI, fasting glucose, HbA1c, and body weight).	Glucose	103-110	CXADR pseudogene 1	Homo sapiens	0-3
34822211-0	2022	Dissociative Adsorption of H2S on Li(110) Surface Using Density Functional Theory Calculations and Car-Parrinello Molecular Dynamics Simulations.	Deuterium	27-30	CXADR pseudogene 1	Homo sapiens	99-102
34802014-6	2022	In this study, we compared the effect of TCRD and TCR-independent activation (TCRI) on CAR-T cell product attributes.	tcrd	41-45	CXADR pseudogene 1	Homo sapiens	87-90
34794795-3	2021	The manufacture of CAR-T cells requires the adoption of GMP-compatible methods and it demands the collection of mononuclear cells from the patient (or from the donor), generally through the apheresis procedure, T cell selection, activation, transduction and expansion ex vivo, and finally storage, usually cryopreserved, until the moment of their use.	guanosine 5'-monophosphorothioate	56-59	CXADR pseudogene 1	Homo sapiens	19-22
34868965-0	2021	Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome-A Wandering Road to Remission.	bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine	11-15	CXADR pseudogene 1	Homo sapiens	16-19
34770032-0	2021	Car/Motorbike Drivers" Willingness to Use and to Pay for Alcohol Interlock in Taiwan.	Alcohols	57-64	CXADR pseudogene 1	Homo sapiens	0-3
34770032-1	2021	This study explored the important factors affecting drunk car/motorbike drivers" willingness to use and pay for alcohol interlocks.	Alcohols	112-119	CXADR pseudogene 1	Homo sapiens	58-61
34840088-0	2022	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.	cilta-cel	14-23	CXADR pseudogene 1	Homo sapiens	38-41
34667217-0	2021	Upregulation of CD22 by Chidamide promotes CAR T cells functionality.	N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide	24-33	CXADR pseudogene 1	Homo sapiens	43-46
34920797-0	2021	(DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France).	descar-t	1-9	CXADR pseudogene 1	Homo sapiens	56-59
34579971-4	2021	METHODS: This retrospective cohort study identified adult patients who received vancomycin either as monotherapy or in combination with PTZ or carbapenem (VAN + CAR) for at least 48 hours at Jiangsu Province Hospital from January 1, 2017, to December 31, 2018.	Vancomycin	80-90	CXADR pseudogene 1	Homo sapiens	161-164
34342035-7	2021	In patients treated with Car-Da, 30.3% had high-risk CA and 30.1% had amp1q and in Da-Car it was 43.3% and 41%, respectively.	amsonic acid	83-85	CXADR pseudogene 1	Homo sapiens	86-89
34342035-8	2021	In the Car-Da cohort, 34.4% experienced early relapse after HDM-ASCT versus 47.4% in the Da-Car cohort.	amsonic acid	11-13	CXADR pseudogene 1	Homo sapiens	7-10
34342035-14	2021	Outcome of Car-DA and outcome of Da-Car were equally poor.	amsonic acid	15-17	CXADR pseudogene 1	Homo sapiens	11-14
34448274-4	2021	Recent advances in CAR technology hold the promise for Treg-functional superiority.	treg	55-59	CXADR pseudogene 1	Homo sapiens	19-22
34407273-1	2021	OBJECTIVE: The main objective of the MACOMBA (Maternity and Control of Malaria-HIV co-infection in Bangui) trial was to show that cotrimoxazole (CTX) is more effective than Sulphadoxine-Pyremethamine-IPTp (IPTp-SP) to prevent placental malaria infection (primary endpoint) among HIV-positive pregnant women with a CD4+ count >=350 cells/mm3 in Bangui, CAR.	Trimethoprim, Sulfamethoxazole Drug Combination	130-143	CXADR pseudogene 1	Homo sapiens	352-355
34407273-1	2021	OBJECTIVE: The main objective of the MACOMBA (Maternity and Control of Malaria-HIV co-infection in Bangui) trial was to show that cotrimoxazole (CTX) is more effective than Sulphadoxine-Pyremethamine-IPTp (IPTp-SP) to prevent placental malaria infection (primary endpoint) among HIV-positive pregnant women with a CD4+ count >=350 cells/mm3 in Bangui, CAR.	sulphadoxine-pyremethamine-iptp	173-204	CXADR pseudogene 1	Homo sapiens	352-355
34592992-5	2021	Here, we report an excellent moisture retention capability of a new carmine cochineal-derived CDs (Car-CDs) for the first time.	cds	94-97	CXADR pseudogene 1	Homo sapiens	99-102
34060421-3	2021	To that end, questionnaire answers of car drivers disclosing their attitudes on the impacts of driving under the influence of alcohol, drugs and fatigue, and their relationship with past crash involvement as car drivers were analysed.	Alcohols	126-133	CXADR pseudogene 1	Homo sapiens	38-41
34445853-2	2021	We aimed to evaluate the relationship between CAR and the coronary artery calcium (CAC) score, Coronary Artery Disease-Reporting and Data System (CAD-RADS) score in patients unknown diagnosis of coronary artery disease (CAD) underwent coronary CTA (Computed Tomography Angiography) and were classified by CAD-RADS scores.	Calcium	74-81	CXADR pseudogene 1	Homo sapiens	46-49
34401788-2	2021	This protocol summarizes the synthetic biology underlying the development of a stringent oxygen-sensitive CAR for in vitro and in vivo preclinical characterization.	Oxygen	89-95	CXADR pseudogene 1	Homo sapiens	106-109
34397048-2	2021	Here a novel and cost-effective nickel catalyzed ortho-CAr-H glycosylation reaction with high regioselectivity and excellent alpha-selectivity is described.	Nickel	32-38	CXADR pseudogene 1	Homo sapiens	55-58
34355630-7	2022	We have found that fatty acids could be useful to contrast side effects during chemotherapeutic drugs therapies; they are also able to block cancer cell metabolic pathways for proliferation and contrast adverse effects, even when they are used in combination with traditional therapies or innovative, like monoclonal antibodies or CAR-T therapy.	Fatty Acids	19-30	CXADR pseudogene 1	Homo sapiens	331-334
34326166-5	2021	Dasatinib was previously identified as a potent kinase inhibitor that switches off CAR T cell functionality.	Dasatinib	0-9	CXADR pseudogene 1	Homo sapiens	83-86
34115706-4	2021	The aim was to evaluate the prognostic value of 18F-FDG PET/CT metabolic parameters for predicting progression-free survival (PFS) and overall survival (OS) following CAR T-cell therapy.	Fluorodeoxyglucose F18	48-55	CXADR pseudogene 1	Homo sapiens	167-170
34264268-8	2021	Our results indicate that common laboratory parameters before lymphodepletion correlate with CAR-T-related toxicities and can help support clinical decisions, such as preemptive toxicity management, hospitalization length, and proper setting for CAR-T administration.	car-t	93-98	CXADR pseudogene 1	Homo sapiens	246-249
34175021-20	2021	INTERPRETATION: A single cilta-cel infusion at the target dose of 0 75 x 106 CAR-positive viable T cells per kg led to early, deep, and durable responses in heavily pretreated patients with multiple myeloma with a manageable safety profile.	cilta-cel	25-34	CXADR pseudogene 1	Homo sapiens	77-80
34114030-2	2021	All of them have been characterized, including X-ray studies of complex (Au(bzp)Cl(Spym)), and these studies have permitted to elucidate that leaving chloride ligand is trans located to CAr atom.	au(bzp)cl	73-82	CXADR pseudogene 1	Homo sapiens	186-189
34114030-2	2021	All of them have been characterized, including X-ray studies of complex (Au(bzp)Cl(Spym)), and these studies have permitted to elucidate that leaving chloride ligand is trans located to CAr atom.	Chlorides	150-158	CXADR pseudogene 1	Homo sapiens	186-189
34181278-4	2021	The IPI was calculated as neutrophil-to-lymphocyte ratio (NLR) x C-reactive protein to albumin ratio (CAR).	diprotin A	4-7	CXADR pseudogene 1	Homo sapiens	102-105
34289897-5	2021	Mechanistically, dasatinib markedly reduced the phosphorylation of Src and Lck, and downregulated the expression of genes involved in CAR signaling pathways, which resulted in the optimization of cell differentiation, exhaustion and apoptosis-related gene expression.	Dasatinib	17-26	CXADR pseudogene 1	Homo sapiens	134-137
35621033-7	2022	Importantly, sCD19-SA-stimulated CD19-targeted CAR-T cells could improve antitumor effects in vivo.	scd19-sa	13-21	CXADR pseudogene 1	Homo sapiens	47-50
34157031-4	2021	Cadmium toxicity induced oxidative damage as shown by decreased seedling growth and photosynthetic pigment production (Chl a, Chl b and Car), rates of O2-evolution, and photochemistry of PS II of Trigonella seedlings, all accompanied by an increase in H2O2 accumulation.	Cadmium	0-7	CXADR pseudogene 1	Homo sapiens	136-139
34145225-2	2021	Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748).	idecabtagene vicleucel	0-22	CXADR pseudogene 1	Homo sapiens	58-61
34204685-2	2021	Our aim was to explore directly, for the first time, whether an aspect of circadian HPA axis activity (the cortisol awakening response: CAR) was associated with greater visual dependency in postural control.	Hydrocortisone	107-115	CXADR pseudogene 1	Homo sapiens	136-139
34108220-7	2021	Our results demonstrate that addition of CCR8 and DNR into CAR T cells can render them effective in solid tumors.	aspartylasparagylarginine	50-53	CXADR pseudogene 1	Homo sapiens	59-62
34212033-13	2021	The thymidine analog mutations-2 (TAM-2) resistance pathway was higher in B CAR than in B PAN.	Thymidine	4-13	CXADR pseudogene 1	Homo sapiens	76-79
34212033-13	2021	The thymidine analog mutations-2 (TAM-2) resistance pathway was higher in B CAR than in B PAN.	Tamoxifen	34-37	CXADR pseudogene 1	Homo sapiens	76-79
34104374-9	2021	After the recent publication of the results of a phase II trial confirming a notable efficacy and acceptable safety profile, idecabtagene vicleucel is the first CAR-T to gain regulatory US Food and Drug Administration approval to treat refractory multiple myeloma patients who have already been exposed to antibodies against CD38, proteasome inhibitors, and immunomodulatory agents and who are refractory to the last therapy.	idecabtagene vicleucel	125-147	CXADR pseudogene 1	Homo sapiens	161-164
34608776-1	2021	OBJECTIVE: To evaluate safety and postoperative outcomes of DP-CAR with resection of one of the lobar hepatic arteries without arterial reconstruction (extended DP-CAR).	Dipyridamole	60-62	CXADR pseudogene 1	Homo sapiens	63-66
34608776-1	2021	OBJECTIVE: To evaluate safety and postoperative outcomes of DP-CAR with resection of one of the lobar hepatic arteries without arterial reconstruction (extended DP-CAR).	Dipyridamole	60-62	CXADR pseudogene 1	Homo sapiens	164-167
34608776-1	2021	OBJECTIVE: To evaluate safety and postoperative outcomes of DP-CAR with resection of one of the lobar hepatic arteries without arterial reconstruction (extended DP-CAR).	Dipyridamole	161-163	CXADR pseudogene 1	Homo sapiens	63-66
34608776-1	2021	OBJECTIVE: To evaluate safety and postoperative outcomes of DP-CAR with resection of one of the lobar hepatic arteries without arterial reconstruction (extended DP-CAR).	Dipyridamole	161-163	CXADR pseudogene 1	Homo sapiens	164-167
35526712-1	2022	In this study, the typical model solubilized and hydrolyzed substrates of protein and carbohydrate were anaerobically fermented at different carbohydrate-to-protein (Car/Pro) ratios to examine volatile fatty acids (VFAs) production and substrate consumption.	Fatty Acids, Volatile	193-213	CXADR pseudogene 1	Homo sapiens	166-169
35526712-2	2022	The highest VFAs yields of 0.71 and 0.72 mg COD/mg CODsubstrate both occurred at Car/Pro ratio of 1 by BSA-dextran and amino acids (AAs)-glucose fermentation, respectively.	Fatty Acids, Volatile	12-16	CXADR pseudogene 1	Homo sapiens	81-84
35526712-2	2022	The highest VFAs yields of 0.71 and 0.72 mg COD/mg CODsubstrate both occurred at Car/Pro ratio of 1 by BSA-dextran and amino acids (AAs)-glucose fermentation, respectively.	Dextrans	107-114	CXADR pseudogene 1	Homo sapiens	81-84
35526712-2	2022	The highest VFAs yields of 0.71 and 0.72 mg COD/mg CODsubstrate both occurred at Car/Pro ratio of 1 by BSA-dextran and amino acids (AAs)-glucose fermentation, respectively.	Amino Acids	132-135	CXADR pseudogene 1	Homo sapiens	81-84
35526712-2	2022	The highest VFAs yields of 0.71 and 0.72 mg COD/mg CODsubstrate both occurred at Car/Pro ratio of 1 by BSA-dextran and amino acids (AAs)-glucose fermentation, respectively.	Glucose	137-144	CXADR pseudogene 1	Homo sapiens	81-84
35526712-3	2022	The limiting processes were hydrolysis and acidogenesis for the higher Car/Pro ratio of 3 and lower Car/Pro ratio of 0.25, respectively.	Proline	75-78	CXADR pseudogene 1	Homo sapiens	71-74
35526712-3	2022	The limiting processes were hydrolysis and acidogenesis for the higher Car/Pro ratio of 3 and lower Car/Pro ratio of 0.25, respectively.	Proline	104-107	CXADR pseudogene 1	Homo sapiens	100-103
35526712-6	2022	Understanding the effects of Car/Pro ratio on VFAs production is of guiding significance for regulating hydrolysis and acidogenesis processes during anaerobic fermentation of organic wastes.	Fatty Acids, Volatile	46-50	CXADR pseudogene 1	Homo sapiens	29-32
35367518-4	2022	Here, we demonstrated that CD19+ tumor cells derived EVs (NALM6-EVs) can carry CD19 antigen and activate CD19 CAR-T cells.	nalm6-evs	58-67	CXADR pseudogene 1	Homo sapiens	110-113
34206444-5	2021	In the present work, we describe the results of structural modifications of compounds designed based on cationic antimicrobial peptides DK5 and CAR-PEG-DK5, derivatized at their N-terminal part with fatty acids with different lengths of carbon chain.	Polyethylene Glycols	148-151	CXADR pseudogene 1	Homo sapiens	144-147
34069244-0	2021	Sensitivity of Intra- and Intermolecular Interactions of Benzo(h)quinoline from Car-Parrinello Molecular Dynamics and Electronic Structure Inspection.	benzo(h)quinoline	57-74	CXADR pseudogene 1	Homo sapiens	80-83
34759138-7	2021	On multivariate analysis, for high CAR, CA19-9 > 300 U / ml and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS.	ca19-9	40-46	CXADR pseudogene 1	Homo sapiens	35-38
35272215-3	2022	In this work, silicon nanowire field-effect transistors are used to develop target modules for an optimized CAR-T cell operation.	Silicon	14-21	CXADR pseudogene 1	Homo sapiens	108-111
35179242-9	2022	ADA-positive patients had a significantly lower CAR copy number than ADA-negative patients at the time of recurrence (P < 0.001).	N-(2-acetamido)iminodiacetic acid	0-3	CXADR pseudogene 1	Homo sapiens	48-51
35253928-1	2022	We evaluated outcomes of 18 patients with isolated extramedullary disease (iEMD) relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with the CD19-directed CAR T cells ARI-0001 in two centers (adult and pediatric), including patients treated in the CART19-BE-01 trial and the consecutive compassionate use program.	cart19-be-01	275-287	CXADR pseudogene 1	Homo sapiens	182-185
35593017-0	2022	A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin.	OZOGAMICIN	143-153	CXADR pseudogene 1	Homo sapiens	81-84
35589772-12	2022	In conclusion, CAR can predict outcomes in patients with unresectable HCC treated with lenvatinib.	lenvatinib	87-97	CXADR pseudogene 1	Homo sapiens	15-18
35623614-2	2022	OBJECTIVES: We evaluated the usage and therapeutic level attainment of VCZ in hematopoietic cell transplant (HCT) and chimeric antigen receptor T cell (CAR-T) therapy patients at our cancer center.	Voriconazole	71-74	CXADR pseudogene 1	Homo sapiens	152-155
35623614-7	2022	Among consecutive HCT and CAR-T recipients at our center, evaluated 6 months pre- or post- HCT/ CAR-T, VCZ was commonly initiated pre- or post-allogeneic HCT (102/381, 26.8%), with most use in the first 30 days post stem cell infusion (40/381, 10.5%); VCZ use was less common in autologous HCT (13/276, 4.7%) and CAR-T (10/153, 6.5%).	Voriconazole	103-106	CXADR pseudogene 1	Homo sapiens	26-29
35240681-2	2022	Patients who relapse after CAR T-cell therapy were not included in the registration study, and reports of PV use after CAR T-cells are limited.	polatuzumab vedotin	106-108	CXADR pseudogene 1	Homo sapiens	119-122
35573050-4	2022	In this study, we use a GMP-compliant platform to engineer CMV-specific T cells to express a second-generation CAR derived from the N6 broadly neutralizing antibody, one of the broadest anti-gp120 neutralizing antibodies.	guanosine 5'-monophosphorothioate	24-27	CXADR pseudogene 1	Homo sapiens	111-114
35468618-3	2022	This single-arm, open label phase 1 study (NCT04155749) aimed to evaluate the safety of novel BCMA-targeting CAR T construct that leverages a completely synthetic antigen binding domain (CART-ddBCMA), which was specifically engineered to reduce immunogenicity and improve CAR cell surface stability.	bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine	94-98	CXADR pseudogene 1	Homo sapiens	109-112
35468618-3	2022	This single-arm, open label phase 1 study (NCT04155749) aimed to evaluate the safety of novel BCMA-targeting CAR T construct that leverages a completely synthetic antigen binding domain (CART-ddBCMA), which was specifically engineered to reduce immunogenicity and improve CAR cell surface stability.	bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine	94-98	CXADR pseudogene 1	Homo sapiens	272-275
35452255-6	2022	We successfully transduced DNTs with a second-generation anti-CD19-CAR (CAR19) without hampering their endogenous characteristics or off-the-shelf properties.	dnts	27-31	CXADR pseudogene 1	Homo sapiens	67-70
35452255-11	2022	These studies demonstrate the potential of using allogeneic DNTs as a platform for CAR technology to provide a safe, effective, and patient-accessible CAR-T cell treatment option.	dnts	60-64	CXADR pseudogene 1	Homo sapiens	83-86
35452255-11	2022	These studies demonstrate the potential of using allogeneic DNTs as a platform for CAR technology to provide a safe, effective, and patient-accessible CAR-T cell treatment option.	dnts	60-64	CXADR pseudogene 1	Homo sapiens	151-154
35563889-2	2022	TAM-mediated suppression of T-cell antitumor reactivity is considered to be a major obstacle for many immunotherapies, including immune checkpoint blockade and adoptive T/CAR-T-cell therapies.	tam	0-3	CXADR pseudogene 1	Homo sapiens	171-174
35007698-4	2022	This review briefly summarizes the T cell metabolic profiles and key metabolic challenges it faces in TME such as nutrient depletion, hypoxia, and toxic metabolites, then emphatically discusses the potential strategies to modulate metabolic properties of CAR-T cells including improving CARs construct design, optimizing manufacture process via addition of exogenous cytokines or targeting specific signaling pathway, manipulating ROS levels balance or relieve the unfavorable metabolic TME including adaptation to hypoxia and relieving inhibitory effect of toxic metabolites, eventually strengthening the anti-tumor response.	ros	431-434	CXADR pseudogene 1	Homo sapiens	255-258
35410313-10	2022	BI-1206 sensitized the efficacy of rituximab monotherapy in a PDX model with triple resistance to rituximab, ibrutinib and CAR T-therapies (p = 0.030).	bi-1206	0-7	CXADR pseudogene 1	Homo sapiens	123-126
35425020-4	2022	Here, we model the polarization of molecular-scale silver inclusions in a magnesium oxide matrix, using the Modern Theory of Polarization and Car-Parrinello Molecular Dynamics (CPMD).	Silver	51-57	CXADR pseudogene 1	Homo sapiens	142-145
35425020-4	2022	Here, we model the polarization of molecular-scale silver inclusions in a magnesium oxide matrix, using the Modern Theory of Polarization and Car-Parrinello Molecular Dynamics (CPMD).	Magnesium Oxide	74-89	CXADR pseudogene 1	Homo sapiens	142-145
35230110-1	2022	In this study, surface diffusion of l-aspartic acid-carvedilol (ASP-CAR) co-amorphous systems at different ASP concentrations is measured and correlated with their physical stability.	Aspartic Acid	36-51	CXADR pseudogene 1	Homo sapiens	68-71
35230110-1	2022	In this study, surface diffusion of l-aspartic acid-carvedilol (ASP-CAR) co-amorphous systems at different ASP concentrations is measured and correlated with their physical stability.	Carvedilol	52-62	CXADR pseudogene 1	Homo sapiens	68-71
34988704-7	2022	The lowest albumin level was found at 7 days after CAR-T cell infusion compared with baseline (P < 0.001), while the levels of triglyceride increased at 14 and 21 days (P < 0.001, P = 0.036).	Triglycerides	127-139	CXADR pseudogene 1	Homo sapiens	51-54
34988704-8	2022	The levels of cholesterol at 7, 14, and 21 days after CAR-T cell infusion were lower than baseline (all P < 0.05).	Cholesterol	14-25	CXADR pseudogene 1	Homo sapiens	54-57
34988704-9	2022	Spearman"s correlation coefficient showed cytokine release syndrome grade was negatively correlated with the levels of albumin at 7 days and cholesterol at 21 days after CAR-T cell infusion (r =  - 0.353, P < 0.001; r =  - 0.395, P = 0.002).	Cholesterol	141-152	CXADR pseudogene 1	Homo sapiens	170-173
34988704-11	2022	The levels of albumin and total cholesterol after CAR-T cell infusion were negatively correlated with the grade of cytokine release syndrome.	Cholesterol	32-43	CXADR pseudogene 1	Homo sapiens	50-53
35091499-0	2022	CAR T-cell Efficacy in Solid Tumors Is Affected by N-glycosylation.	Nitrogen	51-52	CXADR pseudogene 1	Homo sapiens	0-3
35453350-5	2022	Carnosine (beta-alanyl-L-histidine, Car) protects cells from the damage due to the reactive species derived from oxygen (ROS), nitrogen (RNS) or carbonyl groups (RCS).	Oxygen	113-119	CXADR pseudogene 1	Homo sapiens	36-39
35453350-5	2022	Carnosine (beta-alanyl-L-histidine, Car) protects cells from the damage due to the reactive species derived from oxygen (ROS), nitrogen (RNS) or carbonyl groups (RCS).	ros	121-124	CXADR pseudogene 1	Homo sapiens	36-39
35453350-5	2022	Carnosine (beta-alanyl-L-histidine, Car) protects cells from the damage due to the reactive species derived from oxygen (ROS), nitrogen (RNS) or carbonyl groups (RCS).	Nitrogen	127-135	CXADR pseudogene 1	Homo sapiens	36-39
35453350-5	2022	Carnosine (beta-alanyl-L-histidine, Car) protects cells from the damage due to the reactive species derived from oxygen (ROS), nitrogen (RNS) or carbonyl groups (RCS).	Radon	137-140	CXADR pseudogene 1	Homo sapiens	36-39
35453350-6	2022	Car inhibits the degradation of hyaluronan induced by free radical processes in vitro but, like Hy, the potential protective action of Car is drastically hampered by the enzymatic hydrolysis in vivo.	Hyaluronic Acid	32-42	CXADR pseudogene 1	Homo sapiens	0-3
35453350-6	2022	Car inhibits the degradation of hyaluronan induced by free radical processes in vitro but, like Hy, the potential protective action of Car is drastically hampered by the enzymatic hydrolysis in vivo.	Hyaluronic Acid	32-42	CXADR pseudogene 1	Homo sapiens	135-138
35453350-9	2022	Moreover, we tested if the covalent conjugation between Hy and Car inhibits the enzymatic hydrolysis of the polymer and the dipeptide backbone.	Polymers	108-115	CXADR pseudogene 1	Homo sapiens	63-66
35453350-9	2022	Moreover, we tested if the covalent conjugation between Hy and Car inhibits the enzymatic hydrolysis of the polymer and the dipeptide backbone.	Dipeptides	124-133	CXADR pseudogene 1	Homo sapiens	63-66
35323961-0	2022	Enhancing GD2 CAR-T Therapy with IGF1R Blockade: Are DIPG CAR-Ts ready for combinatorial therapy?	dipinacoline glutamate	53-57	CXADR pseudogene 1	Homo sapiens	14-17
35433994-7	2022	In order to understand the possible mechanisms of lenalidomide in CAR-T therapy, CAR-T copies of peripheral blood were regularly detected by quantitative real-time polymerase chain reaction, and an in vitro test was also conducted.	Lenalidomide	50-62	CXADR pseudogene 1	Homo sapiens	66-69
35433994-7	2022	In order to understand the possible mechanisms of lenalidomide in CAR-T therapy, CAR-T copies of peripheral blood were regularly detected by quantitative real-time polymerase chain reaction, and an in vitro test was also conducted.	Lenalidomide	50-62	CXADR pseudogene 1	Homo sapiens	81-84
35433994-9	2022	Furthermore, one case responding to CAR-T therapy initially but suffering a relapse shortly achieved complete remission again after lenalidomide exposure, with an increase in the number of CAR-T copies detected.	Lenalidomide	132-144	CXADR pseudogene 1	Homo sapiens	36-39
35433994-9	2022	Furthermore, one case responding to CAR-T therapy initially but suffering a relapse shortly achieved complete remission again after lenalidomide exposure, with an increase in the number of CAR-T copies detected.	car-t	189-194	CXADR pseudogene 1	Homo sapiens	36-39
35433994-10	2022	The in vitro test showed that lenalidomide could delay the exhaustion of CAR-T cells.	Lenalidomide	30-42	CXADR pseudogene 1	Homo sapiens	73-76
35433994-12	2022	We confirmed that lenalidomide maintenance can improve patients" OS, and the delayed exhaustion of CAR-T cells may contribute to this OS benefit.	Lenalidomide	18-30	CXADR pseudogene 1	Homo sapiens	99-102
35091499-1	2022	N-glycans provide resistance to CAR T-cell therapy, and inhibition of N-glycan synthesis improves CAR efficacy.	n-glycans	0-9	CXADR pseudogene 1	Homo sapiens	32-35
35091499-1	2022	N-glycans provide resistance to CAR T-cell therapy, and inhibition of N-glycan synthesis improves CAR efficacy.	n-glycan	70-78	CXADR pseudogene 1	Homo sapiens	32-35
35091499-1	2022	N-glycans provide resistance to CAR T-cell therapy, and inhibition of N-glycan synthesis improves CAR efficacy.	n-glycan	70-78	CXADR pseudogene 1	Homo sapiens	98-101
35267562-7	2022	DP CAR can be performed with acceptable morbidity and survival.	Dipyridamole	0-2	CXADR pseudogene 1	Homo sapiens	3-6
3527174-8	1986	In mechanism of action studies, CAR was found to inhibit ribonucleotide reductase activity but only at nine times the IC50 of hydroxyurea.	Hydroxyurea	126-137	CXADR pseudogene 1	Homo sapiens	32-35
35209010-7	2022	Finally, time-evolution methods, namely classical molecular dynamics (MD) and Car-Parrinello Molecular Dynamics (CPMD) were employed to shed light onto dynamical nature of liquid n-octanol with emphasis put on metric and vibrational features.	1-Octanol	179-188	CXADR pseudogene 1	Homo sapiens	78-81
35222407-0	2022	Bryostatin Activates CAR T-Cell Antigen-Non-Specific Killing (CTAK), and CAR-T NK-Like Killing for Pre-B ALL, While Blocking Cytolysis of a Burkitt Lymphoma Cell Line.	Bryostatins	0-10	CXADR pseudogene 1	Homo sapiens	21-24
35222407-9	2022	Furthermore, bryostatin inhibited CAR-T mediated cytolysis of the Raji Burkitt lymphoma cell line.	Bryostatins	13-23	CXADR pseudogene 1	Homo sapiens	34-37
35222407-10	2022	Bryostatin increased the cytolysis by CD22 CAR-T for B-ALL cell lines by at least three mechanisms: 1) the previously reported increase in CD22 target cell numbers on the cell surface, 2) the induction of NK ligands, and 3) the induction of ligands that sensitize leukemia cells to activated T cell antigen-non-specific killing.	Bryostatins	0-10	CXADR pseudogene 1	Homo sapiens	43-46
35202265-13	2022	CONCLUSIONS: Patients undergoing a pre-CAR-T cell apheresis are mainly exposed to DEHP, which can impact their health because of its endocrine disruption effect, but could also lead to a decrease in CAR-T cells" efficiency/quality.	Diethylhexyl Phthalate	82-86	CXADR pseudogene 1	Homo sapiens	39-42
35202265-13	2022	CONCLUSIONS: Patients undergoing a pre-CAR-T cell apheresis are mainly exposed to DEHP, which can impact their health because of its endocrine disruption effect, but could also lead to a decrease in CAR-T cells" efficiency/quality.	Diethylhexyl Phthalate	82-86	CXADR pseudogene 1	Homo sapiens	199-202
3527174-1	1986	Preclinical pharmacologic studies of caracemide [N-acetyl-N-(methylcarbamoyloxy)-N"-methylurea; CAR] have demonstrated a marked instability of this compound in the presence of either phosphate buffer (pH 7.4) or human plasma.	caracemide	37-47	CXADR pseudogene 1	Homo sapiens	96-99
35102167-6	2022	To prevent antigen-dependent T cell differentiation, we block CAR signaling and GRP78 cell surface expression post activation by using dasatinib during GRP78-CAR T cell manufacturing.	Dasatinib	135-144	CXADR pseudogene 1	Homo sapiens	62-65
35102167-6	2022	To prevent antigen-dependent T cell differentiation, we block CAR signaling and GRP78 cell surface expression post activation by using dasatinib during GRP78-CAR T cell manufacturing.	Dasatinib	135-144	CXADR pseudogene 1	Homo sapiens	158-161
35094950-13	2022	In our retrospective analysis of 36 patients we showed that single agent high-dose melphalan can achieve high response rates (ORR 66.7%) even in uncontrolled disease enabling consolidation therapy e.g. with allogeneic stem cell transplantation or CAR T-cell therapy.	Melphalan	83-92	CXADR pseudogene 1	Homo sapiens	247-250
3856968-3	1985	A high response rate to low-dose cytosine-arabinoside (LD-CAR) was observed in myeloblastic and promyelocytic leukaemias, but the complete remission rate was low.	Cytarabine	33-53	CXADR pseudogene 1	Homo sapiens	58-61